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The global energy crisis and increasing environmental concerns have spurred the sustainable 
production of biofuels and other fossil-fuel-derived chemicals. One approach is to engineer 
microbial metabolic pathways to convert renewable feedstocks (e.g. lignocellulosic biomass) to 
compounds that have structures similar to those of petroleum-derived fuels and chemicals. The 
microbial fatty acid (FA) biosynthetic pathway is attractive because FAs are common precursors 
that can be converted to several types of chemicals, including alkanes, alkenes, alcohols, and esters. 
These chemicals have numerous applications as fuels, fragrances, emollients, plasticizers, 
thickeners, and detergents. Most work has used Escherichia coli as the microbial host due to its 
exceptionally high rate of fatty acid biosynthesis. 
To broaden the use of FA-derived compounds, it is important to diversify the structure of 
biosynthesized FAs. Unfortunately, wild-type E. coli synthesize only straight long-chain FAs 
(mostly palmitic acid), which limits their range of application. On the other hand, chemicals 
derived from non-natural fatty acids (NNFAs) have wider applications. For example, branched-
chain FA-derived hydrocarbons have better combustion properties than their straight-chain 
counterparts when used as fuels, and ω-hydroxy acids and di-acids are monomers for polymers. 
xii 
 
My dissertation work explored engineering E. coli metabolic pathways to produce NNFAs and 
their derivatives. I started with the production branched-chain fatty acids (BCFAs), and showed 
that high percentage BCFA (or derivatives) production can be achieved via my engineered strains. 
The composition of BCFAs was controlled to produce even-chain-iso-, odd-chain-iso-, or odd-
chain-anteiso-BCFAs separately. Next, I partitioned the complete pathway into three modules: a 
precursor formation module, an acyl-CoA activation and malonyl-ACP consumption module, and 
a final product synthesis module. I engineered and tuned each module separately and combined 
the optimal modules to produce a high percentage of branched-chain fatty alcohols, alkanes, and 
esters. Finally, I established a new cell-free framework as a proof-of-concept for in vitro 
production of fatty acid derivatives, providing a platform for rapid screening and prototyping of 
fatty acid synthetic pathways to produce bifunctional fatty acid derivatives. 
The findings of my work have provided a deeper understanding of the potential of the fatty 
acid synthetic pathway for NNFA production, and the strain-engineering strategies used in this 




Chapter 1: Microbial production of non-
natural chemicals 
1.1 Current progress in microbial bioproduction 
The past decade has witnessed rapid advance in microbial bioproduction from renewable resources. 
Various biosynthetic pathways have been constructed to produce chemicals with diverse structures, 
and multiple metabolic engineering strategies have been developed to increase titers, yields, 
productivities and system robustness. The feedstock choices have been expanded from food crops 
(e.g., corns and oilseeds) to abundant and low-cost non-food biomass (e.g., corn stover and 
switchgrass) [1], solid wastes (e.g., industrial wastes and sewage sludge) [2], natural resources 
(syngas, methanol and methane) [3], and carbon dioxide [4]. Meanwhile, the fermentation host 
choices have expanded beyond the traditional model microorganisms such as Escherichia coli and 
Saccharomyces cerevisiae to a wide variety of non-model organisms. These new hosts variously 
feature unique capabilities in assimilating target feedstock, adapting to specialized fermentation 
conditions, and producing target chemicals in high efficiencies.  
1.2 Strategies for pathway optimization 
Once the metabolic pathway is established, several new strategies can be applied to optimize 
the pathway and to increase product titers, yields, and productivities. Conventional concept of 
metabolic engineering is to drive the metabolic flux into the production pathway. Various methods 
have been developed to facilitate this step, including upregulating pathway enzymes [5], deleting 
or downregulating competing pathways [6], and adjusting the global metabolism by engineering 
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transcriptional factors [7]. Meanwhile, an increasing number of strategies have been developed to 
balance metabolic pathways and to engineer host cells by increasing their robustness, enhancing 
cell viability, and regulating cell populations [8].   
Metabolite overproduction often competes with natural metabolism for limited cellular 
resources and disrupts the host’s homeostasis for some metabolites or cofactors [9], leading to 
impaired cell growth [10]. Therefore, to increase the system robustness and thus to obtain high 
efficient production, engineered metabolic pathway must be balanced by eliminating pathway 
bottlenecks while preventing the accumulation of excess proteins or intermediates. A metabolic 
pathway can be balanced statically via engineering promoters [11] or RBSs [12], or dynamically 
via a metabolite biosensor to adjust flux in response to a rate-limiting or a toxic metabolite by 
regulating its production and/or consumption [13, 14]. An alternative strategy to avoid adverse 
effects on cell growth is to separate the production process from cell growth phase. Several 
strategies were developed to induce the transition from growth phase to production, including 
stationary phase signals [15], quorum sensing [16], and depletion of a nutrient [17] that is not 
needed for metabolite production. For example, based on the Crabtree effect, a GAL regulatory 
circuit was engineered in S. cerevisiae to autosense glucose depletion and simultaneously induce 
the producing pathway [18, 19]. 
Furthermore, the accumulation of some products may trigger a variety of detrimental effects 
on the host cells, mainly physiological changes of cell membranes. By altering the composition of 
cell membranes FA (e.g. chain length, degree of saturation, and abundance of cyclic rings) [20] 
and the distribution of phospholipid head groups [21], the engineered hosts could demonstrate 
enhanced tolerance to various toxic compounds (such as alcohols, carboxylic acids and aromatic 
compounds) and adverse industrial conditions (such as low pH and high temperature) [20].  
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In addition, the heterogeneity of producing cells strongly affects ensemble production [22, 23]. 
A recently developed strategy named PopQC positively links metabolite production with cell 
growth, enabling the enrichment of high-producing variants from a heterologous culture and 
leading to several folds enhancement in overall product titers [24]. Selecting non-genetic variants 
is a promising new path to increase the production yield, with a strong potential for novel 
development based on the system.  
1.3 Metabolic pathways for the synthesis of non-natural 
chemicals 
Typically, based on the inherence of the biosynthetic pathway, the produced chemicals can be 
broadly classified into three categories: 1) Natural chemicals, such as bioethanol and lactic acid, 
which are produced inherently through a native pathway; 2) Non-natural chemicals, such as 1-
butanol and isobutanol, which are produced in a heterologous host strain by the establishment of 
heterologous pathways and enzymes; 3) Non-natural created chemicals, which can only be 
produced by creating synthetic enzymes and pathways with new functions. In this section, I intend 
to give a brief but comprehensive overview of three heterologous pathways leading to non-natural 
chemical production in E. coli. 
1.3.1 α-keto acid pathway  
Isobutanol pathway is a great example for non-natural chemical biosynthesis. By combining 
the short-chain branched-chain amino acid biosynthetic pathway with the alcohol generation 
pathway, short-chain alcohols (including isobutanol, 3-methyl-1-butanol, and 2-methyl-1-butanol) 
were produced from cellular short-chain α-keto acid intermediates catalyzed by an α-keto acid 
decarboxylase and an alcohol dehydrogenase [25](Figure 1-1, light blue). Furthermore, by altering 
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the substrate specificity of LeuABCD enzymes, the acyl chain length of α-keto acids was further 
increased by recursively condensing with acetyl-CoA and releasing CO2. Using this strategy, 
alcohols with medium chain-lengths (up to C8) or with branched/aromatic terminals were 
produced [26] (Figure 1-1, green). Meanwhile, α-keto acids or their derived alcohols can also be 
converted to short-chain acids [27] and alkanes [28], and to acetate-based esters [29].  
Table 1- 1 The carbon efficiencies, cofactor balances, and highest titers produced from α-
keto acid pathway 
Products Carbon recovery from glucose Cofactor imbalance Highest titer  
1-butanol 44.4% + 6 NADH 1 g/L  [30] 
isobutanol 66.7% + 1 NADH, - 1 NADPH 22 g/L  [25] 
3-methyl-1-butanol 55.6% + 4 NADH, - 1 NADPH 4.4 g/L  [31] 
2-methyl-1-butanol 83.3% + 1 NADH, - 3 NADPH 1.25 g/L  [32] 
1-pentanol 41.7% + 8 NADH 4.3 g/L [33] 
1-hexanol 40.0% + 10 NADH 302 mg/L 
[26] 
1-heptanol 38.9% + 12 NADH 80 mg/L [26] 
1-octanol 38.1% + 14 NADH 2.0 mg/L [26] 
 
One advantage of the α-keto acid pathway is its ability to add one carbon atom at a time to the 
acyl-chain, allowing precise control over chain-length. However, this chain elongation process 
sacrifices carbon efficiency and accumulates NADH (Table 1-1), which might be the reason for 




Figure 1- 1 Biofuels produced from the α-keto acid pathway (left) and non-decarboxylative 
Claisen condensation pathway (right) 
α-keto acids can be converted to aldehydes by an α-keto acid decarboxylase (Kivd). Aldehydes 
can then be converted to alcohols by an aldehyde dehydrogenase (AdhE) or to alkanes by an 
aldehyde decarbonylase (colored blue). α-keto acids can be elongated by a LeuABCD mutant to 
yield longer chain α-keto acids (colored green). The natural-occurring non-decarboxylative 
Claisen condensation pathway is colored purple. The engineered primers and extenders used in the 
non-decarboxylative Claisen condensation pathway are colored grey. 
 
1.3.2 Non-decarboxylative Claisen condensation pathway 
Non-decarboxylative Claisen condensation pathway was first discovered in nature from 
Clostridium kluyveri [34] (Figure 1-1, purple). In this pathway, two molecules of acetyl-CoA are 
condensed to acetoacetyl-CoA, which is then reduced to butyrate by β-reduction reactions. In 
contrast to the FA biosynthetic pathway that grows the carbon chain on ACP, the non-
decarboxylative Claisen condensation pathway grows the carbon chain on CoA and uses acetyl-
CoA or other short-chain acyl-CoAs as primers. Dellomonaco et al. engineered a synthetic non-
decarboxylative Claisen condensation pathway to elongate carbon chains by reversing β-oxidation 
pathway [35]. The elongation cycle can be terminated by an acyl-CoA reductase and an alcohol 
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dehydrogenase to produce straight-chain alcohols, or by an acyl-CoA thioesterase to produce 
carboxylic acids. By switching thiolases and β-reduction enzymes, researchers further expanded 
the primer from acetyl-CoA to six other ω-functionalized primers, and incorporated three different 
extender units [36] (Figure 1, grey structures). This platform has greatly enlarged the structural 
diversity of biosynthesized molecules, yielding a series of novel bioproducts, such as 2-
methylpentanoic acid and 2,3-dihydroxybutyric acid [36].  
The non-decarboxylative Claisen condensation pathway has two distinctive advantages: the 
ability to incorporate internal functional groups (including branch structures) into the product, and 
the ability to orthogonally control the structures of both primers and extenders. This pathway will 
become more versatile as new enzymes are discovered to incorporate more extenders and new 
strategies are developed to precisely control the number and order of elongation cycles.   
1.3.3 Isoprenoid pathway 
The isoprenoid pathway utilizes C5 isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP) as building blocks, which are produced from either the mevalonate 
(MVA) or methylerythritol-4-phosphate (MEP) pathway (Figure 1-2). The carbon chain is 
elongated by iterative assembly of IPP or DMAPP, generating polyisoprenoid diphosphates which 
are then converted to terpenes or terpenoids by terpene synthases or polyisoprenoid diphosphate 




Figure 1- 2 The isoprenoid pathway  
Mevalonate pathway is colored light blue. MEP pathway is colored purple. AA-CoA: acetoacetyl-
CoA; MVA: mevalonate; MVAP: mevalonate-5-phosphate; MVAPP: mevalonate-diphosphate; 
MEP: 2-C-methylerythritol-4-phosphate; CDP-ME: 4-diphosphocytidyl-2-C-methylerythritol; 
CDP-MEP: 4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate; HMB-PP: (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate. 
 
Due to the diverse functionality of terpene synthases, the most outstanding feature of the 
isoprenoid pathway is its capability to generate structurally diverse products. So far, thousands of 
different terpene structures have been identified [37], and over hundreds of terpene synthases have 
been sequenced [38]. However, most terpene synthases have not been characterized, and the links 
between most terpene synthases to their corresponding terpene products have not been established. 
New methods for high throughput characterization of new terpene synthases could facilitate the 
discovery of new biosynthetic routes to various specialty chemicals. 
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1.4 Fatty acid pathway 
The commercialization of biodiesel as the first-generation biofuels has attracted much 
attention on fatty acid pathway. As oilseed-derived biodiesel suffers from inferior low-temperature 
performance and competes with food supply, engineering efforts have been made to overproduce 
microbial-based fatty acid-derived fuels and chemicals. Fatty acids (FAs) are biosynthesized in 
vivo by either the discrete fatty acid synthase complex FASII (in most bacteria) or a multifunctional 
FASI synthase (in eukaryotic cells). In E. coli, the initiation step is catalyzed by β-keto-acyl-ACP 
synthetase III (FabH, encoded by fabH), which condenses acetyl-CoA with malonyl-ACP to form 
acetoacetyl-ACP (Figure 1-3). The four-carbon acyl chain is then elongated on acyl carrier proteins 
(ACPs) through repeated cycles of reactions catalyzed by FabG, FabA/FabZ, FabI, and FabB/FabF 
to yield straight long-chain acyl-ACPs for lipid biosynthesis. Straight long-chain acyl-ACP can be 
hydrolyzed by the overexpression of a cytosolic thioesterase to produce SCFAs [39]. Medium-
chain FAs (C8-C12), which are preferred for biodiesel, can be produced in E. coli by 
overexpressing a medium-chain-specific thioesterase [40] (Figure 1-3, Chain-Length Control 
Module). Similarly, the S. cerevisiae FASI has been engineered to produce medium-chain FAs at 
a titer of 464 mg/L using a rational protein engineering strategy [41]. These medium-chain FAs 
can then be derived using engineered conversion pathways to alkanes [42], alcohols [43], and 




Figure 1- 3 Pathways for the production of fatty acid-derived chemicals  
Native E. coli fatty acid pathway is colored grey. The chain length control module is colored purple. 
The α-terminal structure control is colored blue. FabH: β-keto-acyl-ACP synthase III; FabB: β-
keto-acyl-ACP synthase I; FabG: β-keto-acyl-ACP reductase; FabZ: β-hydroxyacyl-ACP 
dehydratase; FabI: enoyl-acyl-ACP reductase; FadD: acyl-CoA synthase; ACR: acyl-CoA 
reductase; AtfA: wax-ester synthase; AAR: acyl-ACP reductase; ADO: aldehyde decarbonylase; 
ADH: alcohol dehydrogenase; FAR: fatty acyl reductase. 
 
Several engineering efforts have been developed to overproduce SCFAs in engineered E. coli 
including overexpression of various thioesterases [45, 46], deletion of genes involved in β-
oxidation (fadD or fadE) [45, 47], engineering global regulators of fatty acid pathways [48], and 
implementing synthetic control systems to dynamically control the expression of pathway genes 
[13, 14]. Through these efforts, SCFAs have been produced in both high titers and yields [14]. 
Overall, the highly efficient natural FAS pathways make fatty acid an attractive intermediate 
for various chemical productions. On the other hand, the essentiality of fatty acid presents 
challenges to engineering: 1) incorporating non-native fatty acids into the cell membrane may 
change the membrane fluidity, inhibiting cell growth, 2) expressing native fatty acid biosynthetic 
genes is often growth-associated, limiting the production to the growth phase, and 3) interaction 
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between natural FAS enzymes may prevent short- and medium-chain acyl-ACPs from interacting 
with desired heterologous enzymes in biosynthetic pathways.  
1.5 Scope of this research 
Current engineering efforts on E. coli fatty acid biosynthetic pathway only produce straight 
chain products, which limits its range of application. On the other hand, chemicals derived from 
non-natural fatty acids (NNFAs) have broad applications. For example, branched-chain-fatty-acid-
derived hydrocarbons have better fuel combustion properties, and ω-hydroxy acids and di-acids 
are monomer starting points for producing polymers. Ideally, diversifying the structure of 
biosynthesized fatty acids from E. coli could produce non-natural molecules that have exactly the 
same chemical structures as petroleum-derived chemicals, and the high rate machinery of E. coli 
fatty acid synthesis will facilitate the broad application of these FA-derived compounds. 
This dissertation aims to engineer E. coli metabolic pathways to produce NNFAs and their 
derivatives. Specifically, I aim to start engineering an E. coli strain to produce branched-chain 
fatty acids (BCFAs) in Chapter 2. Then I apply the engineered platform to produce branched-chain 
hydrocarbons and to develop strategies to optimize pathway robustness, efficiencies, and yields in 
Chapter 3. Finally, I aim to extend the diversity of biologically synthesized fatty acids by testing 
the capacity of the fatty acid biosynthetic pathway to incorporate functional terminal groups based 
on my engineered pathways in Chapter 4 and Chapter 5. Successful completion of this study will 
generate a series of pathways for the biosynthesis of NNFA-derived products, which cannot be 
currently produced from renewable resources. Furthermore, the modular-controlled production 
system will allow the fine tuning of chemical structures and compositions, making it suitable for 
a variety of applications. 
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Chapter 2: Engineer an E. coli strain to 
produce branched-chain fatty acids in high 
percentage 
2.1 Introduction 
Engineering microbial metabolic pathways allows the production of advanced biofuel and 
biochemical with desired structures and properties. Among them, the fatty acid biosynthetic 
pathway is particularly attractive because fatty acids are common precursors that can be readily 
converted to several types of chemicals including alkanes [42, 49], alkenes [50], alcohols [39, 51], 
and esters [52-54] through either biological [55] or chemical conversion [45]. However, the 
majority of previous engineering efforts have focused on microbial production of straight-chain 
fatty acids (SCFAs) and their derivatives, which have limited cold-flow properties and thus can be 
only used during warm weather [56, 57]. The low-temperature operability of fatty acid-derived 
fuels can be improved by introducing branches to the fuel molecule, which requires the synthesis 
of branched-chain fatty acids (BCFAs) [58].  
Naturally, E. coli synthesizes only SCFAs through the multi-enzyme fatty acid type II 
biosynthesis system (FASII). The initiation step is catalyzed by the only β-keto-acyl-ACP 
synthetase III (FabH, encoded by fabH), which condenses acetyl-CoA with malonyl-ACP to form 
acetoacetyl-ACP. Then the four-carbon acyl chain product is elongated on acyl carrier proteins 
(ACPs) through repeated cycles of reactions to yield straight long-chain acyl-ACPs (C14-C18) for 




Figure 2- 1 SCFAs and BCFAs biosynthetic pathways 
 (A) Incorporation of branch groups (R) to fatty acids is determined by the substrate specificity of 
FabH. EcFabH (blue) uses acetyl-CoA as a substrate. Branched-chain-acyl-CoA-specific FabHs 
(red) preferentially use branched-chain acyl-CoAs as substrates. (B) BCFAs produced from this 
study. 
 
Previous studies have shown that FabH plays a key role for the production BCFAs in some 
Gram-positive bacteria. While E. coli FabH (EcFabH) can only take acetyl-CoA, and to a lesser 
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extent, propionyl-CoA as substrates, some FabHs from Gram-positive bacteria such as Bacillus 
subtilis, Listeria monocytogenes, and Staphylococcus aureus use branched-chain acyl-CoAs (such 
as 2-methylpropanoyl-CoA) as starters [59]. Additionally, branched-chain acyl-CoAs can be 
synthesized from α-keto acids by the overexpression of a branched-chain α-keto acid 
dehydrogenases (BKD, encoded by the bkd operon) [54, 60-62]. Using such biochemistry, a BCFA 
biosynthetic pathway was recently constructed by overexpressing the B. subtilis BKD and FabH2 
(BsFabH2) [63] (Figure 2-1A, red arrow). However, the engineered strain only produced a low 
fraction of equivalent BCFAs [63]. Instead, a significant proportion of equivalent SCFAs were co-
produced, making it extremely difficult to separate the desired BCFAs from the predominant 
SCFA products. Thus, it is imperative to increase the proportion of BCFAs in total free fatty acids 
(FFAs).  
I reasoned that the low BCFA titer and proportion are due to the competition of two FabHs 
for the same pool of substrate malonyl-ACP and the higher concentration of acetyl-CoA (substrate 
of EcFabH) compared to branched-chain acyl-CoAs (substrate of BsFabH2). In this chapter, the 
acetyl-CoA-specific E. coli FabH was replaced with a branched-chain-acyl-CoA-specific FabH to 
direct the carbon flux to the synthesis of BCFAs, enhancing BCFA titer by 81-fold compared to a 
strain containing both acetyl-CoA- and branched-chain-acyl-CoA-specific FabHs. Furthermore, 
the overexpression of BKD to synthesize branched-chain-acyl-CoA precursors was discovered 
toxic to E. coli due to depletion of protein lipoylation capacity. Engineering a complementary 
protein lipoylation pathway alleviated the toxicity and improved BCFA production to 276 mg/L 
and 85% of total free fatty acids, the highest BCFA titer and percentage to date. Finally, I achieved 
fine-tuning of BCFA branch positions by engineering the upstream pathway to control the supply 
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of branched-chain acyl-CoAs, eventually producing 181 mg/L BCFAs at 72% of total FFA from 
glucose. 
2.2 Materials and Methods 
2.2.1 Materials and Media 
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA). 
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased 
from Thermo Scientific (Waltham, Massachusetts, USA). All primers were synthesized by 
Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl 
Ester Mix), SCFA standards (GLC-20 and GLC-30) and all the other reagents were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4, 
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2 and micronutrients including 
3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2, and 10 μM 
ZnSO4) containing 2% glucose as carbon source was used for cell growth and fatty acid production. 
2.2.2 Plasmids and strains 
Plasmids used in this study were listed in Table 2-1. Gene encoding S. aureus (SaFabH) was 
codon-optimized for E. coli expression and synthesized by Integrated DNA Technologies 
(Coralville, IA, USA), respectively, whereas other genes were amplified by PCR from templates. 
To create all plasmids (Table 3-1), the corresponding genes were assembled into the backbones of 
BioBrick plasmids [64], using either restriction sites, Golden-Gate DNA assembly method [65], 
or Gibson isothermal assembling method [66].  
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Table 2- 1 Plasmids used in Chapter 2 
Plasmids Replication ori Overexpressed operon Resistance Refs 
pA5a-tesA pA15a P lacUV5-tesA(E.coli) Amp
R This chapter 
pB5c-rfp pBBR1 PlacUV5-rfp Cm
R This chapter 
pE1k-BsfabH2 ColE1 PTrc-fabH2(B.subtilis) Kan
R This chapter 
pB5c-bkd pBBR1 PlacUV5-bkd(B.subtilis) Cm
R This chapter 
pB8k-BsfabH2 pBBR1 PBAD-fabH2(B.subtilis) Kan
R This chapter 
pE8c-bkd ColE1 PBAD-bkd(B.subtilis) Cm
R This chapter 
pSa-PecfabH-BsfabH1 SC101 PecfabH-fabH1(B.subtilis) Amp
R This chapter 
pSa-PecfabH-BsfabH2 SC101 PecfabH-fabH2(B.subtilis) Amp
R This chapter 
pSa-PecfabH-SafabH SC101 PecfabH-fabH (S.aureus) Amp
R This chapter 
pB5c-tesA-bkd pBBR1 PlacUV5-tesA(E.coli)-
bkd(B.subtilis) 
CmR This chapter 
pE8c-tesA-bkd ColE1 PBAD-tesA(E.coli)-
bkd(B.subtilis) 
CmR This chapter 
pE8k-lplA ColE1 PBAD-lplA(E. coli) Kan
R This chapter 
pA5k-fadR-lplA pA15a PlacUV5-fadR-lplA (E. coli) Kan
R This chapter 
pE8c-tesA-
mleuABCD 
ColE1 PBAD-tesA-mleuABCD (E. 
coli) 
CmR This chapter 
pA6k-alsS-ilvCD pA15a PLlacO-1- alsS-ilvCD (E. coli) Kan
R  
 
E. coli DH10B was used for cloning purposes. E. coli strains DH1(ΔfadE) and CL111 [67] (a 
gift from Dr. John Cronan’s Lab, University of Illinois at Urbana-Champaign) were used for fatty 
acid production. Strains BC11-13 were created by transforming the corresponding fabH plasmids 
into CL111 followed by deletion of the Salmonella enterica Serovar Typhimurium fabH (SefabH) 
using P1 transduction [67]. To created strain BC13(ΔKan), Kan antibiotic marker in the genome 
of CL111 strain was deleted using plasmid pCP20 [68]. Plasmid pSa-PecfabH-SafabH was 
transformed into the kan deleted CL111 strain and the SefabH was knocked out by P1 transduction. 
Strain BC33 was created by integrating the bkd operon (lpdV, bkdAA, bkdAB, and bkdB) at the 
fadE locus in the genome under the control of a PLacUV5 promoter using a previously described 
technique [69], followed by transforming plasmid pSa-PecfabH-SafabH and knocking out the SefabH 
by P1 transduction [67]. The corresponding plasmids were then transformed into different parental 
strains to yield all the production strains. 
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Table 2- 2 Strains used in Chapter 2 
Strains Relevant genotype fabH gene Reference 
CL111 UB1005, attHK022::(plsX’fabH; aadA) fabH::kan SefabH [67] 
BC01 DH1(ΔfadE) pB8k-BsfabH2, pE8c-bkd, pA5a-
tesA 
EcfabH BsfabH2 This chapter 
BC02 DH1(ΔfadE) pE1k-BsfabH2, pB5c-bkd, pA5a-
tesA 
EcfabH BsfabH2 This chapter 
SC01 DH1(ΔfadE) pA5a-tesA  EcfabH  This chapter 
SC02 DH1(ΔfadE) pB5c-rfp, pA5a-tesA EcfabH  This chapter 
SC03 DH1(ΔfadE) pE8c-tesA-bkd  EcfabH This chapter 
BC11 CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
BsfabH2 
BsfabH2 This chapter 
BC12 CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
BsfabH1 
BsfabH1 This chapter 
BC13 CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
SafabH 
SafabH This chapter 
BC10A CL111 pSa-PecfabH-BsfabH2 pE8c-tesA-bkd SefabH BsfabH2 This chapter 
BC11A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
BsfabH2, pE8c-tesA-bkd 
BsfabH2 This chapter 
BC12A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
BsfabH1, pE8c-tesA-bkd 
BsfabH1 This chapter 
BC13A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-
SafabH, pB5c-tesA-bkd 
SafabH This chapter 
BC11L CL111 ((plsX’fabH; aadA)::TetA, △Kan, pSa-
PecfabH-BsfabH2, pB5c-tesA-bkd, pE8k-lplA 
BsfabH2 This chapter 
BC13L CL111 (plsX’fabH; aadA)::TetA, △Kan, pSa-
PecfabH-SafabH, pB5c-tesA-bkd, pE8k-lplA 
SafabH This chapter 
BC13FL CL111 (plsX’fabH; aadA)::TetA, △Kan, pSa-
PecfabH-SafabH, pE8c-tesA-bkd, pA5k-fadR-lplA 
SafabH This chapter 
BC30 CL111(△kan) fadE:: bslpdV-bsbkdAA-bsbkdAB-
bsbkdB 
SefabH This chapter 
BC33 CL111(△kan) (plsX’fabH; aadA)::TetA fadE:: 
bslpdV-bsbkdAA-bsbkdAB-bsbkdB pSa-PecfabH-
SafabH 
SafabH This chapter 
BC33C CL111 (plsX’fabH; aadA)::TetA, △Kan, 
fadE::bkd, ldhA::fadR-lplA, pSa-PecfabH-SafabH, 
pE8c-tesA-mleuABCD, pA6k-alsS-ilvCD 
SafabH This chapter 
 
2.2.3 Cell culturing and α-keto acids supplementation 
Cells were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were 
inoculated 2% v/v into M9 minimal medium (described in section 2.2.1) with corresponding 
17 
 
antibiotics for adaptation. Overnight cultures in minimal medium were then used to inoculate 5 
mL of the same fresh minimal medium, with an initial OD600 of 0.08. When OD600 reached 0.8, 
cells were induced with proper inducers (1mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.4% 
arabinose, and/or 200 nM anhydrotetracycline (aTc), or as otherwise specified). For α-keto acid 
supplementation experiments, one of the α-keto acids (3-methyl-2-oxobutyric acid, 3-methyl-2-
oxopentanoic acid, or 4-methyl-2-oxopentanoic acid) was added at OD600 = 0.8 to a final 
concentration of 1 g/L. Cells were harvested three days after induction.   
Cell growth curves were recorded on an Infinite F200PRO (TECAN) plate reader. Overnight 
LB cultures were used to inoculate modified M9 medium with 2% glucose. Overnight cultures 
were then used to inoculate 5 mL of the same fresh minimal medium with an initial OD600 of 0.08. 
Upon inoculation, 150 μl of the culture was aliquoted into a 96-well plate. The 5 mL culture was 
used for fatty acid quantification, while the 96-well plate was incubated inside the plate reader 
with shaking (218.3 rpm, 37 °C) to record cell growth. Relative cell density (in arbitrary units) 
was measured by monitoring absorption at 600 nm. Data were taken every 1500 s until cell cultures 
reached late stationary phase. 
2.2.4 qRT-PCR 
qRT-PCR was performed using a previously published method [70]. Strains DH1(ΔfadE), 
BC13 and BC13A were cultivated as described in section 2.2.3 and induced with 1 mM of IPTG 
and the supplementation of 1g/L 4-methyl-2-oxopentanoic acid. Total RNAs were extracted from 
exponentially growing cells in duplicate using TRIzol Max Bacterial RNA Isolation Kit (life 
technologies). Contaminating DNA was removed with RNase-free DNase I (Thermo Scientific), 
and cDNAs were synthesized using a Revert Aid First Strand cDNA Synthesis Kit (Thermo 
Scientific) with random hexamer primers following the manufacturer’s protocol. The synthesized 
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cDNAs were normalized to 0.2 μg/μL, and 1 μL was amplified using the Power SYBR Green PCR 
Master Mix (Applied Biosystems) and primers specific to the genes of interest in a 20 μL reaction 
system. The reaction for each gene in each sample was performed in triplicates. qRT-PCR assays 
were carried out on an ABI7500 fast machine with the thermal cycling conditions recommended 
by the manufacturer. For data analysis, expression levels of the house keeping gene dnaK were 
used as a control for normalization between samples. Fold changes of genes of interest were 
calculated as 2-ΔΔCT.  
2.2.5 Quantification of the free fatty acids 
Titers of free fatty acids were quantified using a previously published method [48]. 
Specifically, 1 mL of cell culture was acidified with 100 μL of concentrated HCl (12N). Free fatty 
acids were extracted twice with 0.5 mL ethyl acetate, which was spiked with 20 μg/mL of C19:0 
fatty acid as an internal standard. The extracted fatty acids were methylated to fatty acid methyl 
esters (FAMEs) by adding 10 μL concentrated HCl, 90 μL methanol, and 120 μL of TMS-
diazomethane, and incubated at room temperature for 15 min. FAMEs were quantified using a 
GC-MS (Hewlett-Packard model 7890A, Agilent Technologies) equipped with a 30 m DB5-MS 
column (J&W Scientific) and a mass spectrometer (5975C, Agilent Technologies) or a FID 
(Agilent Technologies) detector. For each sample, the column was equilibrated at 80 °C for 1 min, 
followed by a ramp to 280 °C at 30°C/min, and was then held at 280 °C for 3 min. Individual 
BCFA peaks were identified by comparing their retention time to those of standard BCFA methyl 
esters (Bacterial Acid Methyl Ester Mix, Sigma Aldrich) and by comparing their mass spectra to 
the Probability Based Matching (PBM) Mass Spectrometry Library. Concentrations of each fatty 
acid were determined by comparing the area of each FAME peak to a standard curve generated by 
standard FAME mixtures (GLC-20, GLC-30, and Bacterial Acid Methyl Ester Mix, Sigma Aldrich) 
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eluted using the same method. BCFA titer for each strain was measured in biological triplicate 
(starting from three different colonies) and average values are reported.   
2.2.6 Western blotting and protein analysis 
Whole culture, volume normalized by optical density at 600 nm, was incubated with loading 
buffer (2x Laemmli Sample Buffer (Bio-Rad) and β-mercaptoethanol) at 99oC for 10 minutes with 
vigorous shaking. Then, 15 μl of whole culture lysates was loaded onto two 12% polyacrylamide 
denaturing gels and separated by electrophoresis. Gels were duplicated and run in parallel. One 
gel was then stained with Coomassie blue and the other was immunoblotted. For immunoblotting, 
protein was blotted to a polyvinylidine fluoride (PVDF) membrane using a standard protocol 
(Gallagher et al., 2008). Lipoate modified enzymes were detected using a rabbit-anti-lipoyl 
primary antibody (EMD-Millipore) followed by a goat-anti-rabbit secondary antibody conjugated 
to horseradish peroxidase (Santa Cruz Biotechnology). Stained membranes were imaged using a 
GE ImageQuant (LAS 4000 mini). 
2.3 Results 
2.3.1 Construction of BCFA biosynthetic pathway 
I first constructed a BCFA biosynthetic pathway similar to previous work [63]. In detail, the 
B. subtilis BKD complex (encoded by ipdV, bkdAA, bkdAB and bkdB), BsFabH2, and a cytosolic 
E. coli thioesterase TesA (encoded by ‘tesA) were overexpressed in a fadE deleted E. coli DH1 
background. The resulting strain (BC01) only produced 0.9% BCFAs at a titer of 2.7 mg/L (Figure 
2-2). No significant increase in BCFA titer or proportion was observed even with the enhanced 
expression level of BsFabH2 by changing its promoter from a relative weak (about one third of 
expression level compared to standard) PBAD (induced with 0.4% arabinose in the presence of 2% 
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glucose in the medium) to a very strong (about 4 times of expression level compared to standard) 
Ptrc (induced with 1 mM of IPTG) [64] (from 2.7 mg/L, 0.9% in BC01 to 3.5 mg/L, 1.9% in BC02, 
Figure 2-2). In both cases, SCFAs were the dominant products (Supplementary Figure 2-1A). The 
low BCFA proportion is consistent with previous studies [63, 71].  
2.3.2 Replacement of EcFabH with branched-chain-specific FabHs 
The key enzyme for the production of SCFA v.s. BCFAs is FabH, which catalyzes the 
condensation of malonyl-ACP and acetyl-CoA in the case of SCFAs or the condensation of 
malonyl-ACP and a branched-chain acyl-CoA in the case of BCFAs. Overexpression of BsFabH2 
in previously engineered E. coli strains resulted in two FabHs competing for malonyl-ACP [63, 
71]. In these strains, the EcFabH may outcompete BsFabH2 because the specific activity of EcFabH 
to acetyl-CoA is 3-6 folds higher than the activity of BsFabH2 to branched-chain acyl-CoAs based 
on in vitro characterization [59]. Furthermore, acetyl-CoA is abundant in E. coli (0.61 mM) [72], 
but it is difficult to accumulate branched-chain acyl-CoAs to concentrations close to or higher than 
acetyl-CoA. As a result, SCFAs were produced predominantly (>98%) even when BsFabH2 was 




Figure 2- 2 BCFA titers produced by engineered E. coli strains in this study  
EcFabH, SeFabH, BsFabH2, and SaFabH are FabHs from E. coli, S. enterica, B. subtilis, and S. aureus, 
respectively. Cells were cultivated as described in Method. BCFA titers from biological triplicate 
were averaged. Numbers above the column indicate the proportions of BCFA over total FFA 
production.     
 
I hypothesized that deletion of EcFabH (complete replacement of EcFabH by BsFabH2) will 
attenuate the synthesis of SCFAs. Although BcFabH2 also recognizes acetyl-CoA as a substrate, 
its specific activity to acetyl-CoA is 24% and 30% lower than that to 2-methylpropanoyl-CoA and 
3-methylbutyryl-CoA, respectively [59]. However, direct replacement of EcFabH with a branched-
chain-acyl-CoA-specific FabH is technically challenging because 1) fabH is essential for fatty acid 
biosynthesis [67], and 2) it is the second gene in a fab operon that contains several essential genes 
 
Strain name BC01 BC02 BC10A BC11A BC13A BC13A BC13B 
fabH promoter PBAD Ptrc PecfabH PecfabH PecfabH PecfabH PecfabH 
EcFabH or SeFabH + + + - - - - 
BsFabH2 + + + + - - - 
SaFabH - - - - + + + 
α-keto acid supply - - - - - + - 
α-keto acid 
synthetic pathway 




in E. coli fatty acid biosynthesis [73]. To solve this problem, I used a previously engineered E. coli 
strain (CL111) [67], whose fabH was already replaced by an acetyl-CoA-specific S. enterica fabH 
(with similar activity with EcFabH) at the attHK022 phage attachment site [67]. I cloned the B. subtilis 
fabH2 (BsfabH2) 3’ of the E. coli fabH promoter (PecfabH) to a low copy number plasmid (SC101 
ori) and transformed the resulting plasmid pSa-PecfabH-BsfabH2 to CL111, leading to strain BC10 
that have both SefabH and BsfabH2 genes (Table 2-2). The SefabH in BC10 was then removed by a 
genetic manipulation that involved P1 transduction of a Tn10 transposon near the attHK022 
attachment site to yield strain BC11 that contained BsfabH2 as the only fabH gene. Both BC10 and 
BC11 were transformed with a plasmid encoding BKD and TesA (pE8c-tesA-bkd), resulting in 
strains BC10A and BC11A, respectively. When cultivated under the same condition, strain BC11A 
produced 17.5 mg/L of BCFAs, which is 35-fold higher than the strain with both SefabH and 
BsfabH2 (BC10A, 0.5 mg/L, Figure 2-2). The BCFA proportion was also increased to 11%, 43-
fold higher than that of BC10A.   
I then used the fabH replacement method to test two more FabHs (BsFabH1, SaFabH), whose 
specificity to branched-chain acyl-CoAs are even higher than BsFabH2 [59, 74]. Strain BC12A 
expressing BsFabH1 (encoded by BsfabH1 gene), BKD, and TesA produced 19.4 mg/L of BCFAs, 
representing 39-fold increase as compared to BC10A. More interestingly, strain BC13A 
expressing SaFabH (encoded by SafabH gene), BKD, and TesA produced 40.3 mg/L of BCFAs, 
corresponding to 81-fold enhancement from BC10A (Figure 2-2). Even compared to strain BC01 
which cannot undergo β-oxidation, the BCFA titer of strain BC13A is 15-fold higher. The 
proportion of BCFAs was also increased to 29% and 27% in strains BC12A and BC13A, 
respectively. In general, the engineered strains produced a variety of BCFAs with chain length 
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spanning from C13 to C17 and carrying different terminal structures (iso and anteiso) (Figure 2-
1B).  
 
Figure 2- 3 Effects of FabH replacement on BCFA production 
Cells were cultivated as described in Methods. BC10A-BC12A were induced with 0.4% arabinose 
while BC13A was induced with 1 mM IPTG. 
 
Next, BCFA profiles of these strains were analyzed. Although strains BC11A-BC13A 
expressing different FabHs, their BCFA profiles are similar: C15:0-anteiso-FA is the most 
abundant BCFA following by either C15:0-iso- or C16:0-iso-FA (Figure 2-3). However, in vitro 
characterization of these FabHs showed different preference towards acyl-CoA substrates [74]. 
For example, the activity of BsFabH1 to 2-methylbutyryl-CoA was 10-fold higher than 3-
methylbutyryl-CoA, whereas the activity of BsFabH2 was 2-fold higher than that to 3-
methylbutyryl-CoA [59]. The inconsistency between the in vitro FabH specificities and in vivo 
BCFA profiles strongly indicated that BCFA production in the engineered strains was limited by 
the branched-chain acyl-CoAs supply. 
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2.3.3 Supplementation of α-keto acids 
In the engineered strains, branched-chain acyl-CoAs are biosynthesized by BKD from 
branched-chain α-keto acids (3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and 3-
methyl-2-oxopentanoic acid), which are naturally produced as precursors for the biosynthesis of 
valine, leucine and isoleucine, respectively. The intracellular α-keto acids pool might be limited 
because biosynthesis of branched amino acids is heavily feedback regulated in E. coli [75-77]. 
Thus, it is possible that the production of BCFAs was limited by the supply of branched-chain α-
keto acids. To test these hypotheses, I supplemented each of the following α-keto acids: 3-methyl-
2-oxobutyric acid (converted 2-methylpropanoyl-CoA), 4-methyl-2-oxopentanoic acid (converted 
3-methylbutyryl-CoA), and 3-methyl-2-oxopentanoic acid (converted 2-methylbutyryl-CoA), to 





Figure 2- 4 Effect of α-keto acid supplementation to BCFA productions 
Strain BC13A (containing SaFabH) was cultivated as described in Methods and induced with 1 
mM of IPTG. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3-
methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns), 
3-methyl-2-oxopentanoic acid (C, solid columns), or nothing (A-C, empty columns). (D) BC13A 
cell cultures were titrated with varied IPTG concentrations. 
 
Supplementation of 1 g/L of 3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and 
3-methyl-2-oxopentanoic acid to strains BC11-13A significantly enhanced the production of even-
chain-iso-FAs, odd-chain-iso-FAs, and odd-chain-anteiso-FAs, respectively (Figure 2-4&5, 
Supplementary Figure 2-2&3), confirming that supply of branched-chain acyl-CoAs (more 
specifically, α-keto acids) limited the synthesis of BCFAs. The specific enhancement also 
confirmed that BCFAs were produced through the designed pathways. Interestingly, I observed 
that supplementation of each α-keto acid also inhibited the production of BCFAs derived from the 
other two α-keto acids (Figure 2-4, Supplementary Figure 2-2&3), presumably due to the 
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competition of α-keto acids for available BKD activity. These results indicated that the conversion 
of α-keto acids to branched-chain acyl-CoAs is a rate-limiting step for the engineered strains when 
supplied with 1 g/L of α-keto acids. The cross-inhibition also demonstrated that the composition 
of BCFAs can be controlled by the supply of α-keto acids. For example, when 4-methyl-2-
oxopentanoic acid was supplemented to the culture of BC13A (carrying SaFabH), odd-chain-iso-
FAs were produced as the predominant BCFAs (95%, Figure 2-4B). On the other hand, when 3-
methyl-2-oxopentanoic acid was supplemented to the culture of BC13A, odd-chain-anteiso-FAs 
were produced as the predominant BCFAs (>99%, Figure 2-4C). Among the tested conditions, 
supplementing 4-methyl-2-oxopenoate to BC13A produced the highest BCFA titer, 93 mg/L, and 
the highest BCFA proportion, 43% (Figure 2-5). 
 
Figure 2- 5 Total BCFA titers (A) and proportions (B) for strains BC11-13A with and without 
α-keto acid supplementation. 
 
Next, the transcriptional responses to the replacement of E. coli native fabH with other fabHs 
was investigated. The transcription levels of fabD and fabG, two downstream genes in the fab 
operon, were analyzed by qRT-PCR (Figure 2-6). Compared to the wide type strain DH1 (ΔfadE), 
the transcription levels of both fabD and fabG were lower in strain BC13 and BC13A, suggesting 
that the fabH replacement affected the transcription of downstream genes. This might give some 
explanation for the relatively low total fatty acid production in the engineered strain. However, the 
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expression level of fabD increased in strain BC13A compared to that in strain BC13 (Figure 2-6), 
likely results from the overexpression of tesA. Because the increased acyl-CoA concentration due 
to the accumulation free fatty acids will help activate FadR expression, which can further activate 
the PfabH promoter. 
 
Figure 2- 6 Fold changes of transcription levels of fabD and fabG in strain BC13 and BC13A 
compared to wide type strain DH1(ΔfadE) 
 
2.3.4 Heterologous BKD expression restricts lipoylation of E. coli native 2-
oxoacid dehydrogenases  
I further titrated the culture of BC13A with varying concentrations of inducer IPTG to find 
the optimal expression level for TesA and BKD. The highest BCFA titer was obtained when 0.1 
mM of IPTG was used, yielding 126 mg/L BCFAs, corresponding to 52% of the total FFAs (Figure 
2-4D, Supplementary Figure 2-1B). In contrast, induction with 1 mM IPTG caused stress to the 
cell and led to modification to the plasmid encoding the BKD and TesA (data not shown).  
Next, the impact of BKD and/or TesA overexpression on cell growth and free fatty acid (FFA) 
production was elucidated individually. To start with, I constructed a FFA-overproducing strain, 






















to strain SC01, resulting in strain SC03. BKD overexpression significantly reduced cell growth 
when compared to strain SC03, p<0.01 (Figure 2-7A). Expression of a red fluorescent protein 
(RFP, strain SC02) did not affect cell growth, indicating that the impaired cell growth was likely 
not caused by metabolic burden from protein expression. When strains SC01 and SC03 were 
cultivated for FFA production, a significant reduction in total FFA occurred with BKD 
overexpression, indicating that BKD expression also inhibits total FFA production (Figure 2-7B).  
 
Figure 2- 7 Expression of BKD reduces cell growth and free fatty acid production 
 (A) Growth of fatty acid-overproducing strains with (SC03) or without (SC01) BKD 
overexpression (p<0.01, Student’s T-test). (B) Overexpression of BKD reduced free fatty acid 
(FFA) production (p<0.01). Data generated by and figure courtesy of Dr. Gayle Bentley. 
 
In the quest to understand the observed BKD toxicity, I examined the highly conserved OADH 
enzyme class.  Previous work determined that overexpression of the PDH E2 subunit in E. coli 
repressed PDH activity, suggesting that E. coli has limited protein lipoylation capacity [78]. 
Expression of heterologous BKD requires lipoylation of its E2 subunit, which might similarly 
deplete the cellular lipoylation capability, leading to unlipoylated PDH and OGD in addition to 
under-lipoylated BKD (Figure 2-8A, Panel ii). Because both PDH and OGD contribute to central 
metabolism, I hypothesized that BKD overexpression without expanded lipoylation capacity 
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restricts lipoylation of PDH and OGD (Figure 2-8A, ii), resulting in the observed growth defect 
and reduced fatty acid production (Figure 2-7).   
 
Figure 2- 8 Expression of BKD reduces lipoylation of native 2-oxoacid dehydrogenases 
(OADHs) 
(A) Model illustrating the proposed mechanism of BKD toxicity. (i) Native 2-oxoacid 
dehydrogenases (OADHs, blue) are lipoylated for proper function. (ii) When BKD (yellow) is 
overexpressed, protein lipoylation capability is depleted, leading to unlipoylated OADHs. (iii) 
OADHs can be fully lipoylated through the overexpression of LplA, which ligates lipoic acid to 
the E2 subunit of each OADH. (B) Top, 12% SDS-PAGE gel stained with Coomassie blue; bottom, 
Western Blot of the same samples blotted using an anti-lipoyl monoclonal antibody. Conditions 
for each Western sample are listed beneath each lane. Data generated by and figure courtesy of Dr. 
Gayle Bentley. 
 
To test my hypothesis, whole cell lysates of strains with (SC03) or without BKD (SC01) 
overexpression were analyzed by SDS-PAGE and Western Blot using an anti-lipoyl-protein 
monoclonal antibody (Figure 2-8B). Without BKD, I observed lipoylated proteins corresponding 
to the molecular weights of the PDH E2 subunit (62 kDa) and the OGD E2 subunit (44 kDa, lane 
1 in Figure 2-8B). Strain SC03 with BKD overexpression showed a strong lipoyl-protein band 
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corresponding to the size of the BKD E2 subunit (45 kDa, cannot be resolved with the 44 kDa 
OGD E2), but the previously visible band of lipoylated-PDH E2 disappeared (Lane 2 in Figure 2-
8B). Overall, this data revealed that BKD overexpression depletes lipoylation of E. coli native 
OADHs, leading to impaired cell growth (Figure 2-7A) and reduced FA production (Figure 2-7B).  
2.3.5 Engineering a protein lipoylation pathway restores OADH lipoylation, 
allowing BCFA production in high percentages 
I hypothesized that the protein lipoylation deficiency caused by BKD overexpression could be 
overcome by engineering a protein lipoylation pathway. E. coli utilizes two pathways for protein 
lipoylation (Figure 2-9). The first pathway synthesizes lipoate de novo, for which an octanoyl 
moiety from octanoyl-ACP is transferred to an E2 subunit, followed by insertion of two sulfur 
atoms into the octanoyl side chain of an octanolyated E2 subunit, forming a five membered ring 
(Figure 2-9, red arrows) [79-82]. Alternatively, exogenous lipoic acid can be ligated directly to an 
E2 subunit by lipoyl ligase A (LplA, encoded by lplA) (Figure 2-9, blue arrow) [83-85]. To test 
the hypothesis, a strain was engineered to utilize exogenous lipoic acid, in order to maximize the 
availability of octanoyl-ACP for fatty acid elongation. The lplA gene was cloned under the control 
of a PBAD promoter and transformed to strain BC11A, resulting in strain BC11L. Overexpression 
of LplA on a plasmid partially improved PDH lipoylation (Lane 3 in Figure 2-8B). Completing 
the lipoylation pathway via lipoic acid supplementation further improved PDH E2 and BKD E2 
lipoylation (Lane 4 in Figure 2-8B), demonstrating that the engineered pathway improved 




Figure 2- 9 Engineered pathway for the production of high percentage branched-chain fatty 
acids (BCFAs) in E. coli 
The percentage of BCFA products can be dramatically enhanced by engineering protein 
lipoylation, either through an endogenous pathway (overexpression of LipB and LipA) or an 
exogenous pathway (LplA overexpression in combination with lipoic acid supplement). Cellular 
branched-chain α-ketoacid precursors can be enriched by engineering a branched-chain amino acid 
biosynthesis pathway (eg. AlsS, IlvCD, and LeuABCD). Data generated by and figure courtesy of 
Dr. Gayle Bentley. 
 
Then I tested whether lipoylation restoration could increase BCFA titer and percentage. 
Without lipoic acid supplementation, strain BC11L produced 49 mg/L BCFA, statistically 
indistinguishable from its parental strain lacking plasmid LplA (BC11A, Figure 2-10A). 
Supplementing lipoic acid in the BC11L culture dramatically improved BCFA production by 4-
fold, reaching 200 mg/L and 81% compared to 29% BCFA without plasmid LplA (BC11A, Figure 
2-10A). BCFA production alone in BC11L surpassed total FFA in the parental strain BC11A, 
suggesting that lipoylation additionally improved cellular capacity for fatty acid production, 
presumably by improving cell fitness through native OADH lipoylation. Among the produced 
BCFAs, odd-chain-iso FAs, 11-methyldodecanoic acid (C13 iso) and 13-methyltetradecanoic acid 
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(C15 iso), are the major products, individually representing 34% and 53% of total FFAs, 
respectively (Figure 2-10B). Lipoic acid added to a strain lacking LplA (BC11A) did not affect 
fatty acid production (data not shown). Furthermore, leaky expression of LplA (without arabinose, 
PBAD-lplA) restored BCFA production to the same level as with fully induced LplA, consistent 
with its role as a protein-modifying enzyme rather than a metabolic enzyme (data not shown). 
Similarly, when SaFabH was used instead of BsFabH2, BCFA production was improved with LplA 
overexpression (Strain BC13L; 220 mg/L, 79% BCFA) compared to the parental strain lacking 
LplA (Strain BC13A; 126 mg/L, 56% BCFA) (Figure 2-10C&D). Expression of FadR, a global 
regulator of fatty acid biosynthesis [48, 86], further increased BCFA production to 276 mg/L and 
85% of total FFA (Strain BC13FL, Figure 2-10C&D). Overall, the results demonstrated that 
engineering the protein lipoylation pathway promotes native OADH and BKD lipoylation, leading 




Figure 2- 10 LplA expression with lipoic acid supplementation increases BCFA production 
(A) FFA production from strains expressing BsFabH2 as the sole FabH. Strain BC11A was 
modified to overexpress LplA (BC11L) (B) fatty acid species produced by each strain, under the 
same condition as the bar in (A). (C), (D) Strains expressing the SaFabH as the sole FabH. Strain 
BC13A was engineered to express a plasmid LplA, generating strain BC13L. Expression of FadR 
in strain BC13L generates strain BC13FL. All cultures (C), (D) were supplemented with 50 mg/L 
lipoic acid. All cultures (A)–(D) were supplemented with 1 g/L 4-methyl-2-oxopentanoate. Data 
generated by and figure courtesy of Dr. Gayle Bentley. 
 
I next supplemented different kinds of α-keto acids to tailor the chain structures of produced 
BCFAs. The highest performing strain, BC13FL, was cultured and supplemented with 1 g/L 3-
methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, or 3-methyl-2-oxopentanoic acid. 
BCFA production strictly mirrored the branch structure of the supplemented α-ketoacid, 
generating even-chain-iso, odd-chain-iso, and odd-chain-anteiso fatty acids as the major products, 
respectively (Figure 2-11). Under all conditions, BCFA production exceeded 83% of total FFA. 
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Specifically, when supplemented with 4-methyl-2-oxopentanoic acid, 93% of BCFA were odd-
chain-iso fatty acids. Likewise, when supplemented with 3-methyl-2-oxopentanoic acid or 3-
methyl-2-oxobutyric acid, 93% and 74% of BCFA produced were odd-chain-anteiso or even-
chain-iso fatty acids, respectively.  
 
Figure 2- 11 Production of high percentage even chain iso, odd chain iso, and ante-iso BCFA 
species 
Strain BC13FL was supplemented with 1 g/L of 4-methyl-2-oxopentanoic acid, 3-methyl-2-
oxopentanoic acid, or 3-methyl-2-oxobutyric acid, separately. (A) FFA profiles of the strain under 
each cultivation condition are shown. (B) Percent of BCFAs corresponding to each branch position 






2.3.6 Production of BCFA from glucose 
After releasing the lipoylation bottleneck, I attempted to generate BCFA from glucose by 
engineering the branched-chain amino acid pathway to enrich for branched-chain α-ketoacid 
precursors (Figure 2-9). In order to accommodate additional genes required for the branched-chain 
amino acid pathway, several operons were integrated into the genome at strategically selected 
integration loci to simultaneously eliminate competing pathways. I first integrated the bkd operon 
at the fadE locus to reduce potential metabolic burden caused by BKD overexpression and to 
prevent potential BCFA consumption in β-oxidation. Next, a synthetic operon containing fadR-
lplA was integrated at the ldhA locus to direct flux away from D-lactate production. Meanwhile, 
the B. subtilis alsS and the E. coli ilvCD gene clusters were expressed to convert pyruvate to 3-
methyl-2-oxobutyric acid (Figure 2-9). An engineered E. coli leuABCD operon carrying a 
feedback-resistant leuA was expressed together with tesA to convert 3-methyl-2-oxobutyric acid 
to 4-methyl-2-oxopentanoic acid [87]. Overall, the resulting strain BC33L overexpressed 15 
enzymes and produced 181 mg/L BCFAs from glucose, comprising 71% of total FFA (Figure 2-
12A&B). As expected, 13-methyl-tetradecanoic acid (C15 iso) was the major FA species (72% of 




Figure 2- 12 Production of BCFA from glucose  
Strain BC33C contains an engineered 4-methyl-2-oxopentanoic acid-producing pathway to 
generate BCFA from glucose (A) Percent composition of straight chain fatty acid (SCFA) and 
BCFA of strain BC33C (B) Free fatty acid species produced by strain BC33 from glucose. Data 
generated by and figure courtesy of Dr. Gayle Bentley. 
 
2.4 Discussion 
Previously, several groups attempted to engineer E. coli to produce BCFAs, but the highest 
BCFA percentage was 20% [71], implying a limit to the percentage of BCFA that can be produced 
in E. coli, a strictly SCFA-producing organism. In this chapter, I have demonstrated the capability 
to engineer E. coli to generate a high percentage of BCFA. By the deletion of E. coli native fabH, 
I have increased the BCFA proportions (strain BC13A, 52% in the presence of 4-methyl-2-
oxopentanoic acid) without sacrificing BCFA titers. Furthermore, I demonstrated that incomplete 
protein lipoylation restricted previous BCFA production and a high percentage of BCFA (85% of 
total FFA) can be produced in E. coli by engineering its protein lipoylation pathway. Production 
of a high proportion of BCFA is key to improve the property of FA-derived fuels because 
separation of BCFAs from SCFAs represents significant technical challenges. These approaches 
provide a complementary strategy to other engineering efforts.       
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Furthermore, while branched-chain-acyl-CoA-specific FabH is essential for incorporating 
branches to FAs, I found its overexpression in the presence of EcFabH did not increase BCFA 
production (strain BC02 compared to BC01). In fact, when BsFabH2 expression level was 
increased by changing from a medium strength promoter (PBAD in the presence of 0.4% arabinose 
and 2% glucose) to a strong promoter (Ptrc induced with 1 mM IPTG), total FFA titer decreased 
(from 284 mg/L to 183 mg/L). This observation is consistent with previous findings where FabH 
at concentrations higher than other FASII enzymes inhibited fatty acid production from an in vitro 
reconstructed FASII [88]. Similar inhibition of total FA production by BsFabH2 was also observed 
during the development of strain JBEI-7802. Although FASII enzymes are expressed as separate 
polypeptide chains, effects of relative protein concentrations to FA production suggests interaction 
between FASII proteins, probably in a fashion similar to the integrated type I FAS. Optimizing the 
expression level of branched-chain-acyl-CoA-specific FabHs might alleviate such inhibition, 
further enhancing BCFA production.   
2.5 Conclusion 
In general, I have demonstrated that replacing the acetyl-CoA-specific FabH with one of the 
three tested branched-chain-acyl-CoA-specific FabHs increased the titer of BCFAs up to 81-fold 
relative to the strain containing both FabHs and engineering a protein lipoylation pathway restored 
protein lipoylation and further increased the biosynthesis of BCFA. Moreover, even-chain-iso, 
odd-chain-iso, and odd-chain-anteiso fatty acids can be separately produced by supplying 3-
methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and 3-methyl-2-oxopentanoic acid to 
growth media, respectively, indicating the capability to control the terminal group of FAs. 
Engineering the 4-methyl-2-oxobutyric acid biosynthetic pathway allowed producing odd-
chain-iso fatty acids at up to 181 mg/L, and BCFA percentage up to 79% from glucose. As BCFAs 
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are important precursors for the production of biofuels with improved cold flow properties, the 
method to increase BCFA production by replacing EcFabH and engineering a protein lipoylation 









Supplementary Figure 2-1. Fatty acid production profiles of (A) strain BC01 (containing 
EcFabH& BsFabH2) and (B) the top-performing strain, BC13A (containing SaFabH), with the 











































































































































































Supplementary Figure 2-2. Effect of α-keto acid supplementation to BCFA productions. Strain 
BC11A (containing BsFabH2) was cultivated as described in Methods and induced with 0.4% 
arabinose. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3-
methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns), 
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Supplementary Figure 2-3. Effect of α-keto acid supplementation to BCFA productions. Strain 
BC12A (containing BsFabH1) was cultivated as described in Methods and induced with 0.4% 
arabinose. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3-
methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns), 
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Chapter 3: Modular pathway engineering for 
the production of branched-chain fatty 
alcohols 
3.1 Introduction 
Finite energy resources and increased environmental concerns demand the development of 
sustainable and renewable approaches to the production of fuels, chemicals, and materials. 
Engineering microbial metabolic pathways to synthesize desired products is an attractive approach. 
With recent advances in genetic techniques and metabolic engineering methodologies, various 
engineered microbes have been developed to produce an array of chemicals derived from 
inexpensive and renewable substrates [55, 89] . Target molecules are typically designed to replace 
or mimic those obtained from petroleum or other non-renewable sources [90, 91]. Among these 
chemicals, long-chain fatty alcohols (LCFLs) in the range of C12 to C18 have numerous 
applications as fuels, emollients, plasticizers, thickeners, and detergents [92-94]. At the industrial 
scale, LCFLs are currently produced either through hydrogenation of pretreated natural fats and 
oils (oleochemicals) or hydroformylation of petrochemicals (e.g. crude oil, natural gas) [43, 95, 
96]. Because both processes require harsh reaction conditions and release harmful byproducts to 
the environment [97], microbial production of fatty alcohols from renewable sugars is a promising 
alternative. 
LCFLs have been recently biosynthesized from engineered microbes through fatty acid 
biosynthetic pathway [43, 92, 97-101]. The majority of previously biosynthesized LCFLs contain 
straight aliphatic chains. Straight LCFLs have relatively high freezing points and viscosities 
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compared to their branched-chain isomers, thus limiting their low-temperature operability—an 
essential feature for industrial emollients, lubricants, detergents, and most especially, diesel fuels 
[102, 103]. For example, the most abundant biosynthetically produced LCFL, straight-chain 
palmityl alcohol (C16, often called cetyl alcohol), melts at 49.3°C and exists as a solid at room 
temperature, making it difficult to use as a lubricant or an aircraft hydraulic fluid [104]. In 
comparison, the branched isomer, isocetyl alcohol, is a clear liquid at room temperature (melting 
point -30°C) with significantly enhanced fluidity and low-temperature operability, and thus is used 
in a number of detergent formulations that require low-temperature operability [105]. Introducing 
degrees of unsaturation has been used as an alternative method to improve the fluidity of straight-
chain molecules [106]. However, these molecules are vulnerable to oxidation and color instability, 
both of which do not occur in BLFLs, even at high temperatures and pressures [103]. BLFLs 
additionally are ranked low in eye and skin irritation, allowing their use in cosmetics and 
fragrances [102]. Given the clear breadth BLFL applications, chemical engineers have developed 
methods to synthesize naturally scarce BLFLs [107-109]. BLFLs are currently produced from 
straight LCFLs using a multi-step, catalytic process that requires high temperature (180-300°C), 
strong acids/bases, and multiple operation unites, and the conversion process is unpredictable 
[102]. Recently, branched-short-chain alcohols in the range of (C3 to C7) were produced by 
engineered microbes [26, 110] as gasoline replacements. However, due to their short chain-length 
and high volatility, branched-short-chain alcohols are not suitable for the above-mentioned 
applications. Given BLFLs’ lack of natural abundance, their complex synthesis process, and the 
demand for their distinctive properties, it is imperative to develop biosynthetic approaches to 




Figure 3- 1 Biosynthetic pathways for BLFL production 
α-Keto Acid Generation Module (Module A) converts pyruvate to α-keto acid: 3-methyl-2-
oxobutyric acid or 4-methyl-2-oxopentanoic acid. Acyl-ACP Generation Module (Module B) 
incorporates α-keto acid to the fatty acid biosynthetic pathway. Alcohol Formation Module 
(Module C) converts branched-chain acyl-ACPs to BLFLs. 
 
 
Since straight LCFLs have been biologically or chemically derived from free fatty acid 
precursors [111], BLFLs theoretically can be derived from branched-chain fatty acids (BCFAs). 
BCFAs have been recently biosynthesized in engineered E. coli by overexpressing a heterologous 
branched-chain α-keto acid dehydrogenase complex (BKD), a branched-chain-acyl-CoA-specific 
β-ketoacyl-acyl-carrier protein (FabH) and a thioesterase (TesA) [112, 113]. This system 
ultimately produced BCFA in high percentages from glucose (181 mg/L and 80% BCFA) by 
engineering a protein lipoylation pathway and an α-keto acid biosynthetic pathway. However, 
highly efficient conversion of BCFAs to BLFLs has not been explored. It was not known whether 
the branched-chain intermediates, such as branched long-chain acyl-ACPs, BCFAs, and branched 
long-chain acyl-CoAs, are compatible with alcohol-conversion enzymes, even though some 
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enzymes have activities towards branched short-chain-ACP or CoA intermediates [114, 115]. 
Furthermore, because the BLFL pathway involves in multiple untested reaction, balancing 
activities of each sub-pathway to prevent accumulation of branched-chain intermediate is 
necessary to obtain high titer and yield [116-119].  
To achieve these goals, I constructed and tested four metabolic pathways that convert 
branched-chain acyl-ACPs to BLFLs. To optimize productivity, the entire BLFL pathway was 
divided into three modules (Figure 3-1): an α-Keto Acid Synthesis Module that converts glucose 
to α-keto acids, an Acyl-ACP Generation Module that converts α-keto acids to branched-chain 
acyl-ACPs, and an Alcohol Formation Module that converts branched-chain acyl-ACPs to final 
branched-chain products. To begin, I experimentally determined the most efficient enzyme 
combinations to convert branched-chain acyl-ACPs to BLFLs using an engineered 
branched-chain-acyl-ACP-producing basal strain (BC33). This initial pathway identification 
allowed us to ascertain whether BLFL production was even feasible, given the available enzymes. 
Next, I optimized each module separately and later the entire pathway collectively to produce 
even-chain-iso and odd-chain-iso fatty alcohols from glucose. This modular approach enabled the 
isolation of each module for testing and optimization, without confounding the system by 
simultaneously engineering the other modules. 
3.2 Materials and Methods 
3.2.1 Materials and Media 
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA). 
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased 
from Thermo Fisher Scientific (Waltham, Massachusetts, USA). All primers were synthesized by 
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Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl 
Ester Mix), SCFA standards (GLC-20 and GLC-30), and all the other reagents were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4, 
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2, and micronutrients, 
including 3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2, 
and 10 μM ZnSO4) containing 2% glucose and 0.5% yeast extract as carbon sources was used for 
cell growth and fatty alcohol production.  
3.2.2 Plasmids and strains 
Plasmids used in this study were listed in Table 3-1. Genes encoding S. elongatus AAR (aar), 
M. marinum CAR (car), and B. subtilis Sfp (sfp) were codon-optimized for E. coli expression and 
synthesized by Integrated DNA Technologies (Coralville, IA, USA). Genes encoding ACR 
(maqu2507) and Maqu2220 (maqu2220) were amplified by PCR from templates provided by Dr. 
Brett M. Barney (University of Minnesota, MN) and Dr. Jay D. Keasling (Joint BioEnergy Institute, 
CA). To create all plasmids (Table 3-1), the corresponding genes were assembled into the 
backbones of BioBrick plasmids [64], using either restriction sites or Golden-Gate DNA assembly 
method [65].  
E. coli DH10B was used for cloning purposes. E. coli strain CL111 [67] was used for 
production purposes. Strains BO33A-J were created by transforming the corresponding plasmids 
(Table 3-2) into BC33 competent cells, respectively. Strain BC43 was created by switching native 
leuABCD promoter PleuLp and PleuLp2 to PlacUV5 promoter, using a previously described CRISPR-
Cas9 gene replacement method [120]. Similarly, to create strain BC63, the fadR-lplA operon under 
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the control of a PLacUV5 promoter was integrated to the ldhA locus of BC43 strain by the same 
CRISPR-Cas9 gene replacement method. Strains BO63V and BO63L were created by 
transforming the corresponding plasmids into strain BC63. 
3.2.3 Cell culturing and α-keto acids supplementation 
Cells were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were 
inoculated 2% v/v into M9 minimal medium (described in section 3.2.1) with corresponding 
antibiotics for adaptation. Overnight cultures in minimal medium were then used to inoculate 5 
mL of the same fresh minimal medium, with an initial OD600 of 0.08. When OD600 reached 0.8, 
cells were induced with proper inducers (1mM IPTG, 0.4% arabinose, and/or 200 nM aTc, or as 
otherwise specified). For α-keto acid supplementation experiments, one of the α-keto acids (3-
methyl-2-oxobutyric acid or 4-methyl-2-oxopentanoic acid) was added at OD600 = 0.8 to a final 
concentration of 1 g/L. Cells were harvested three days after induction.   
3.2.4 Fermentation 
Fed-batch fermentation was carried out using a New Brunswick Bioflo 110 fermenter with a 
pH meter, a dissolved oxygen electrode, and a temperature electrode. M9 medium (described in 
section 2.1, 500 mL) was inoculated with an overnight culture of strain BO63L to an initial OD600 
to 0.08, along with appropriate antibiotics and 0.001% Antifoam 204. The fermentation was 
initiated with the following settings: Temperature was set to 30 °C, pH was controlled at 7.4 by 
automatic feeding of 6N ammonium hydroxide, the airflow rate was kept at 1.5 L/min, and the 
average stirring rate was maintained at 500 rpm. Gene expression was induced at OD600 = 10 by 
addition of 1 mM IPTG, 0.4% arabinose, and 0.22 μM aTc (final concentration). A glucose stock 
solution (400 g/L glucose and 12 g/L MgSO4) was intermittently pulsed into the bioreactor to re-
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supply glucose, and a yeast extract solution (20%) was intermittently added into the bioreactor. 
Broth samples (~3 ml) were collected at a series of time points to measure cell density and alcohol 
titer.  
3.2.5 Quantification of the fatty alcohols 
For the quantification of alcohols, 1 mL of cell culture was acidified with 100 μL of 
concentrated HCl (12N). Alcohols were extracted twice with 0.5 mL ethyl acetate, and the organic 
layers were isolated. Next, 200 μL of the organic layer from each sample was transferred to one 2 
mL clear glass GC vial (Agilent Technologies, Santa Clara, CA), mixed with 200 μL of N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% v/v chlorotrimethylsilane, and incubated 
at 60 °C for 2 h. Alcohol derivatives were quantified using a GC-MS (Hewlett-Packard model 
7890A, Agilent Technologies) equipped with a 30 m DB5-MS column (J&W Scientific) and a 
mass spectrometer (5975C, Agilent Technologies) or a FID (Agilent Technologies) detector. For 
each sample, the column was equilibrated at 80 °C, followed by a ramp to 300 °C at 20°C/min, 
and was then held at 300 °C for 3 min. Individual alcohol peaks were identified by comparing their 
retention time to that of a standard (a mixture of 1-tetradecanol, 1-hexadecanol, and 1-octadecanol, 
prepared and derivatized identically to samples) and by comparing their mass spectra to the 
National Institute of Standards and Technology (NIST) Mass Spectral Library. Concentrations of 
each alcohol were determined by comparing the area of each sample peak to a standard curve 
generated by standards eluted using the same method. Product titer for each strain was measured 
in biological triplicate (starting from three different colonies) and average values are reported. 
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Table 3- 1 Plasmids used in Chapter 3 
Plasmids Replication ori Overexpressed operon Resistance Reference 
pSa-PecfabH-SafabH SC101 PecfabH-SafabH (S. aureus) Amp
R Chapter 2 
pB5k-aar-lplA pBBR1 PlacUV5-aar(S. elongatus)-lplA(E. coli) Kan
R This chapter 
pB5k-sfp-car pBBR1 PlacUV5-sfp(B. subtilis)-car(M. marinum) Kan
R This chapter 
pE8c-tesA-lplA ColE1 PBAD-tesA(E. coli)-lplA(E. coli) Cm
R This chapter 
pB5k-maqu2507-lplA pBBR1 PlacUV5-maqu2507(M. aquaeolei VT8)-lplA(E. coli) Kan
R This chapter 
pE5c-tesA-fadD ColE1 PlacUV5-tesA(E. coli)-fadD(E. coli) Cm
R [121] 
pB5k-maqu2220 pBBR1 PlacUV5-maqu2220(M. aquaeolei VT8) Kan
R [121] 
pB5k-maqu2220-lplA pBBR1 PlacUV5-maqu2220(M. aquaeolei VT8)-lplA(E. coli) Kan
R This chapter 
pB5k-adhA pBBR1 PlacUV5-adhA(L. lactis) Kan
R This chapter 
pB5k-yqhD pBBR1 PlacUV5-yqhD(E. coli)  Kan
R This chapter 
pB5k-yjgB pBBR1 PlacUV5-yjgB(E. coli)  Kan
R This chapter 
pA8c-aar-lplA pA15a PBAD-aar(S. elongatus)-lplA(E. coli) Cm
R This chapter 
pB2k-alsS-ilvCD-yjgB pBBR1 Ptet-alsS(B. subtilis)-ilvCD(E. coli)-yjgB(E. coli) Kan
R This chapter 
pE2c-aar-lplA-yjgB ColE1 Ptet-aar(S. elongatus)-lplA(E. coli)-yjgB(E. coli) Cm
R This chapter 
pA6k-alsS-ilvCD pA15a PLlacO-alsS(B. subtilis)-ilvCD(E. coli) Kan
R [122] 
pB2k-alsS-ilvCD pBBR1 Ptet-alsS(B. subtilis)-ilvCD(E. coli) Kan
R This chapter 
pB5c-aar-lplA-yjgB pBBR1 PlacUV5-aar(S. elongatus)-lplA(E. coli)-yjgB(E. coli) Cm
R This chapter 
pB5c-maqu2220-lplA pBBR1 PlacUV5-maqu2220(M. aquaeolei VT8)-lplA(E. coli) Cm
R This chapter 
pA8c-leuAmutBCD pA15a PBAD-leuA
mutBCD(E. coli) CmR This chapter 
pE8c-leuAmutBCD ColE1 PBAD-leuA
mutBCD(E. coli) CmR This chapter 
pB5k-maqu2220-leuAmutBCD pBBR1 PlacUV5-maqu2220(M. aquaeolei VT8)-leuA
mutBCD(E. 
coli) 
KanR This chapter 
pA8c-lplA pA15a PBAD-lplA(E. coli) Cm
R This chapter 
pE8c-adhA ColE1 PBAD-adhA(L. lactis) Cm
R This chapter 
pE8c-yqhD ColE1 PBAD-yqhD(E. coli) Cm
R This chapter 
pE8c-yjgB ColE1 PBAD-yjgB(E. coli) Cm
R This chapter 
pE2s-alsS-ilvCD ColE1 Ptet-alsS(B. subtilis)-ilvCD(E. coli) Spec
R This chapter 
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Table 3- 2 Strains used in Chapter 3 
Strains Relevant genotype Reference 
Parental strains 
CL111 UB1005, attHK022::(plsX’fabH; aadA) fabH::kan [67] 
CL111(△kan) UB1005, attHK022::(plsX’fabH; aadA), △kan Chapter 2 
BC30 CL111(△kan) fadE:: bslpdV-bsbkdAA-bsbkdAB-bsbkdB Chapter 2 




mut This study 
BC63 BC43 ldhA::fadR-lplA This study 
Alcohol-producing strains 
BO33A BC33 pB5k-aar-lplA This study 
BO33B BC33 pB5k-sfp-car, pE8c-tesA-lplA This study 
BO33C BC33 pB5k-maqu2507-lplA, pE5c-tesA-fadD This study 
BO33D BC33 pB5k-maqu2220-lplA This study 
BO33E1 BC33 pA8c-aar-lplA, pB5k-adhA This study 
BO33E2 BC33 pA8c-aar-lplA, pB5k-yqhD This study 
BO33E3 BC33 pA8c-aar-lplA, pB5k-yjgB This study 
BO33E4 BC33 pE2c-aar-lplA-yjgB This study 
BO33F BC33 pA8c-aar-lplA, pB2k-alsS-ilvCD-yjgB This study 
BO33F1 BC33, pE2c-aar-lplA-yjgB, pA6k-alsS-ilvCD This study 
BO33F2 BC33, pE2c-aar-lplA-yjgB, pB2k-alsS-ilvCD This study 
BO33F3 BC33, pB5c-aar-lplA-yjgB, pA6k-alsS-ilvCD This study 
BO33G1 BC33, pA8c-leuAmutBCD, pB5k-aar-lplA This study 
BO33G2 BC33, pE8c-leuAmutBCD, pB5k-aar-lplA This study 
BO33H1 BC33 pB5k-maqu2220-lplA, pE8c-adhA This study 
BO33H2 BC33 pB5k-maqu2220-lplA, pE8c-yqhD This study 
BO33H3 BC33 pB5k-maqu2220-lplA, pE8c-yjgB This study 
BO33I1 BC33, pA6k-alsS-ilvCD, pB5c-maqu2220-lplA This study 
BO33I2 BC33, pE2k-alsS-ilvCD, pB5c-maqu2220-lplA This study 
BO33J1 BC33, pA8c-leuAmutBCD, pB5k-maqu2220-lplA This study 
BO33J2 BC33, pA8c-lplA, pB5k-maqu2220-leuAmutBCD  This study 
BO43I BC43 pB5c-maqu2220-lplA, pE2s-alsS-ilvCD This study 
BO63V BC63 pB5k-maqu2220, pE2s-alsS-ilvCD This study 




3.3.1 Engineering Alcohol Formation Modules in BCFA-producing strains 
To create the branched-chain-acyl-ACP-producing basal strain BC33, the E. coli fabH was 
first replaced by Staphylococcus aureus fabH (SafabH), a modification which was previously 
demonstrated to enhance branched-chain fatty acid production [113]. The acyl-CoA 
dehydrogenase gene (fadE) was next replaced by Bacillus subtilus bkd, functionally inhibiting β-
oxidation (ΔfadE) and allowing the activation of branched-chain α-keto acids to branched-chain 
acyl-CoAs that can enter the FASII system (ΔfadE::bkd) (Table 3-1 & 2). Next, three Alcohol 
Formation Modules were separately constructed in strain BC33 (Table 3-2), resulting in alcohol-
producing strains BO33A-C. Strain BO33A utilizes the Synechococcus elongatus acyl-ACP 
reductase (AAR, encoded by aar, Figure 3-1) to convert acyl-ACPs to fatty aldehydes [99]. Strain 
BO33B first generates FFAs via expression of the E. coli cytosolic thioesterase (TesA), which are 
then converted to fatty aldehydes by the Mycobacterium marinum carboxylic acid reductase (CAR, 
encoded by car) with Bacillus subtilis Sfp (encoded by sfp) coexpression [92] (Figure 3-1). Strain 
BO33C also expresses cytosolic TesA to generate FFAs and overexpresses an E. coli acyl-CoA 
synthetase (FadD) to activate FFAs to fatty acyl-CoAs, which are then converted to aldehydes by 
overexpressing an acyl-CoA reductase from Marinobacter aquaeolei VT8 (ACR, encoded by 
maqu2507) [123] (Figure 3-1). All strains rely on native E. coli alcohol dehydrogenases (ADHs) 
to reduce aldehydes to alcohols. The native E. coli lipoyl ligase (encoded by lplA) is also expressed 
in all strains to improve the lipoylation of 2-oxoacid dehydrogenases including BKD, which 







Figure 3- 2 Testing three Alcohol Formation Modules 
(a) Overall titer distribution and (b) chain-length of three BLFL-producing strains with different 
Alcohol Formation Modules, BO33A-C (Table 3-2). SeAAR, MmCAR, and MaMaqu2507 are 
reductases from S. elongatus, M. marinum, and M. aquaeolei VT8, respectively. (c-d) Effect of 
alcohol dehydrogenase overexpression on BLFL production. Alcohol profiles of strain BO33A 
(without adh overexpression) are compared with those from strain BO33E1 (expressing adhA from 
L. lactis), BO33E2 (expressing yqhD from E. coli), and BO33E3 (expressing yjgB from E. coli). 
All cultures were supplemented with 1 g/L 4-methyl-2-oxopentanoic acid. Cells were cultivated 




I first sought to test the three Alcohol Formation Modules by assessing their capacities to 
convert branched-chain acyl-ACPs to BLFLs. Strains BO33A-C were cultivated at previously 
determined optimal temperatures for each pathway (See methods) [92, 98, 124] and supplemented 
with 1 g/L of 4-methyl-2-oxopentanoic acid, the most favorable α-keto acids for BCFA production 
[113]. Each strain produced some BLFLs, representing the first report of BLFL production in E. 
coli. The CAR pathway (BO33B) and the ACR pathway (BO33C) produced 28 mg/L and 18 mg/L 
BLFLs, respectively. In addition, the chain lengths of the products range from C14 to C18, 
consistent with the FFA profile of the TesA-overexpressing strain [39]. Meanwhile, the AAR 
pathway (BO33A) produced the highest BLFL titer among these three strains: 54 mg/L, 
comprising 84% of the total fatty alcohols (Figure 3-2a). The branch and chain-length profile of 
BLFLs produced in BO33A is consistent with the profile of BCFAs produced by strains with 
similar genetic backgrounds as previously reported (Figure 3-2b) [112], indicating that the AAR 
pathway has little preference between straight-chain and branched-chain acyl-ACP substrates. 
Interestingly, the CAR pathway produced 2-fold more straight-chain fatty alcohols but 6-fold less 
BLFLs than the AAR pathway, indicating that the CAR pathway is primarily straight-chain-
specific. While these results serve as a proof-of-principle that BLFL can be produced at high 
percentages in E. coli, the initial low titers indicate that additional engineering efforts are needed 
to obtain desirable titers and yields of branched-chain products.  
All of the above strains relied upon E. coli native ADHs to convert fatty aldehydes to alcohols. 
I next sought to increase BLFL production in strain BO33A by overexpression of ADHs. Three 
unique ADHs, adhA from Lactoccocus lactis [122], and yqhD and yjgB [92, 122, 125] from E. coli, 
were overexpressed in strain BO33A, resulting in strains BO33E1, BO33E2, and BO33E3, 
respectively. When cultivated under the same conditions and with 1 g/L 4-methyl-2-oxopentanoic 
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acid, strains BO33E1 and BO33E2 produced 85 and 69 mg/L BLFLs, respectively (Figure 3-2c & 
2d). Strain BO33E3 produced 130 mg/L BLFLs, comprising 83% of total alcohols, a 2.4-fold 
enhancement over BO33A. Specifically, 73 mg/L of 15-methylhexadecanol and 42 mg/L of 13-
methyltetradecanol were produced (Figure 3-2c), converting 8% of the supplemented 4-methyl-2-
oxopentanoic acid and making odd-chain-iso alcohols the major BC alcohol species. Both BO33E1 
and BO33E3 had similar fatty alcohol production profiles to that of strain BO33A, indicating that 
AdhA and YjgB did not selectively determine chain length or structure. In addition, no aldehyde 
was detected in BO33E3 culture, indicating the conversion of aldehyde to alcohol is complete. 
3.3.2 Engineering 3-methyl-2-oxobutyric acid Generation Module to produce 
even-chain-iso fatty alcohols from glucose  
Modular pathway assembly can facilitate step-wise optimizations. With the downstream 
Alcohol Formation Module optimized, I next sought to improve the production of BLFL from 
glucose by engineering and optimizing the α-Keto Acid Generation Module. In this module, I built 
upon the downstream-optimized strain BO33E3 to add the capacity for even-chain-iso fatty 
alcohol production from glucose via the precursor 3-methyl-2-oxobutyric acid (Figure 3-3a). 
Since the B. subtilis alsS and the E. coli ilvCD have been used to accumulate intracellular 3-
methyl-2-oxobutyric acid, I first cloned them with yjgB under the control of a strong Ptet promoter 
in a medium-copy-number BBR1 origin plasmid (Table 3-1). The resulting plasmid, pB2k-alsS-
ilvCD-yjgB, was co-transformed with pA8c-aar-lplA (aar and lplA under the control of a PBAD 
promoter in a pA15a origin plasmid) into strain BC33. Cultivation of the resulting strain BO33F 
in the absence of α-keto acid supplementation produced 34 mg/L of BLFLs, comprising 44% of 
the total alcohols (Figure 3-3b, Supplementary Figure 3-1). Because the composition of the α-keto 
acid determines the final chain structure, the final BLFL composition should mirror the cellular 
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pool of α-keto acids. The titer of even-chain-iso BLFLs produced by strain BO33F is 14 mg/L, 
lower than the 25 mg/L produced by strain BO33E3 when supplemented with 3-methyl-2-
oxobutyric acid. It should be noted that the odd-chain-iso BLFLs are elongated from 4-methyl-2-
oxopentanoic acid, which is generated from 3-methyl-2-oxobutyric acid. The comparable total 
BLFL production of these two strains, including both even-chain-iso and odd-chain-iso BLFLs, 
indicates that the 3-methyl-2-oxobutyric acid Generation Module was effective, although higher 




Figure 3- 3 Balancing three modules to produce even-chain-iso fatty alcohols  
Plasmids with different copy numbers and promoters are used to optimize the expression level of 
the involved pathways. (a) Biosynthetic pathways for the production of even-chain-iso fatty 
alcohols. (b) Titers of even-chain, odd-chain, and total BLFL of engineered strains. Plasmids with 
different copy numbers and promoters were employed to bear the involved genes in different 
strains. The copy number of the plasmids are defined as low (L), medium (M), and high (H). For 
strain BO33E3-4, 1 g/L 3-methyl-2-oxobutyric acid was supplemented. 
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3.3.3 Optimizing 4-methyl-2-oxopentanoic acid Generation Module to produce 
odd-chain-iso fatty alcohols 
In E. coli, the leuABCD operon converts 3-methyl-2-oxobutyric acid to 4-methyl-2-
oxopentanoic acid, which is the precursor for odd-chain-iso BLFL biosynthesis. Previous work 
demonstrated that the ribosome binding sequence (RBS) of native leuA results in weak translation 
initiation, and leuA is heavily negatively auto-regulated by free leucine synthesized from 4-methyl-
2-oxopentanoic acid [87] (Figure 3-4a). In this study, I engineered a mutant operon leuAmutBCD 
that contained a feedback-resistant leuA [87] and a strong synthetic 
RBS(TTTAAGAAGGAGATATACAT). The leuAmutBCD was cloned in either a low (pA15a) or 
a high (pColE1) copy number plasmid to create two engineered strains, BO33G1 and BO33G2, 
respectively. To test the conversion efficiency of the leuAmutBCD operon, both strains were 
supplemented with 3-methyl-2-oxobutyric acid (the substrate for LeuABCD, Figure 3-4a) during 
cultivation. Fully functional leuAmutBCD would result in odd-chain-iso BLFL compositions in a 
similar ratio to the previous best-performing strain (strain BO33A) when supplemented with 4-
methyl-2-oxopentanoic acid. Strain BO33G1 produced 50 mg/L total BLFL and 47 mg/L odd-
chain-iso fatty alcohol, statistically indistinguishable from the BLFL titer of strain BO33A 
supplemented with 4-methyl-2-oxopentanoic acid (Figure 3-4b, Supplementary Figure 3-2). Strain 
BO33G1 generated 94% odd-chain-iso fatty alcohol, indicating complete conversion of 3-methyl-
2-oxobutyric acid by the modified LeuAmutBCD. Conversely, when leuAmutBCD was expressed 
under the high copy number plasmid (strain BO33G2), the BLFL titers decreased (p = 0.07) and 
had large standard variations (Figure 3-4b), even when the inducer concentration was reduced. 
Furthermore, overexpression of leuAmutBCD from the high-copy number plasmid also decreased 
cell growth rate and cell density (Data not shown). These results indicate that expression of the 
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leuAmutBCD operon at too high a level affects cell growth and BLFL production, thus needs to be 
avoided.  
 
Figure 3- 4 Optimizing the 4-methyl-2-oxopentanoic acid Generation Module to produce 
odd-chain-iso fatty alcohols 
(A) Biosynthetic pathways for the production of odd-chain-iso fatty alcohols. (B) Titers of 
engineered odd-chain-iso BLFL-producing strains. Strains BO33G1-2 containing leuAmutBCD in 
plasmids with different copy numbers were cultivated as described in Methods and supplemented 





3.3.4 Balancing gene expression levels in all three modules for enhanced BLFL 
production from glucose 
With the α-Keto Acid Generation and the Alcohol Formation modules optimized separately, 
I next sought to balance the gene expression levels within the completed pathway. I selected the 
best-performing genetic elements of each individual module to complete the full pathway: the α-
Keto Acid Generation Module, including alsS & ilvCD, the Acyl-ACP Synthesis Module, 
including aar & lplA, and the Alcohol Formation Module, including yjgB (Figure 3-3a). To 
perform this optimization, I altered gene copy numbers to change the expression level of each 
module. Compatible plasmids with three different copy numbers were used for this purpose: a high 
copy number (pColE1, 50 copies per cell), a medium copy number (pBBR1, 17-20 copies per cell), 
and a low copy number (pA15a, 7-10 copies per cell) [64] (Figure 3-3b, Supplementary Figure 3-
1). Three additional strains BO33E4, BO33F1, and BO33F2 were created (Figure 3-3b, 
Supplementary Figure 3-1). All three strains expressed aar, lplA, and yjgB from the high copy 
number plasmids under the control of a very tight promoter (Ptet), but produced less BLFL than 
strains BO33E3 and BO33F, which expressed aar, lplA, and yjgB from the low or the medium 
copy number plasmid. The low titer is potentially caused by the insolubility of highly 
overexpressed AAR [99]. Meanwhile, compared to strain BO33F3 with the low-copy alsS-ilvCD 
expression, strain BO33F with the medium-copy alsS-ilvCD expression improved BLFL 
production by 3.2-fold. These results suggest that the optimal aar expression level was medium to 
low, and that alsS-ilvCD required overexpression in a medium to high-copy number plasmid for 
optimal BLFL production (Figure 3-3b, Supplementary Figure 3-1).   
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3.3.5 BLFL production from glucose using the acyl-ACP reductase Maqu2220 
During the course of this work, Haushalter et al. published the production of straight LCFLs 
in high titers by overexpression of a marine acyl-ACP reductase, Maqu2220 from M. aquaeolei 
VT8 [121]. Maqu2220 was first characterized as a fatty aldehyde reductase, reducing fatty 
aldehydes to fatty alcohols [126]. However, it was later confirmed to have acyl-ACP reductase 
activity and is capable of converting acyl-ACPs or acyl-CoAs directly to fatty alcohols [127], thus 
significantly simplifying the fatty alcohol pathway. I tested the efficiency of BLFL production via 
Maqu2220 by replacing the S. elongatus aar in strain BO33A with maqu2220, resulting in strain 
BO33D. When supplemented with 1 g/L of 4-methyl-2-oxopentanoic acid, BO33D produced 198 
mg/L (89%) BC alcohols, 3.7-fold higher than that of strain BO33A (Figure 3-5). Even compared 
with the previous best-performing strain BO33E3, the BLFL titer of strain BO33D enhanced by 
1.5-fold. Most BLFLs (> 99%) were identified in the cell pellet, consistent with previous study 
[128]. Moreover, overexpression of the ADHs yjgB, yqhD, or adhA did not enhance BLFL titer 
(Figure 3-5), further confirming the previous hypothesis that Maqu2220 contains a catalytic 




Figure 3- 5 BLFL profiles of engineered E. coli strains containing Maqu2220 
While strain BO33D does not contain additional adh, BO33H1-3 overexpressed L. lactis adhA, E. 
coli yqhD, and E. coli yjgB, respectively. BLFL profiles are compared with that of strains BO33E3 
(the best performing strain in section 3.1). All cultures were supplemented with 1 g/L 4-methyl-2-
oxopentanoic acid. 
 
After confirming the capability of Maqu2220 to convert branched-chain acyl-ACPs to BLFLs, 
I sought to use Maqu2220 to produce BLFLs from glucose by applying the knowledge learned 
from optimizing the α-Keto Acid Synthesis Module. After constructing and validating strains, I 
found that the optimal expression level of each module mimicked those characterized using the 
aar pathway. First, the high-copy number-expression (pColE1) of the alsS-ilvCD operon increased 
even-chain-iso fatty alcohol production by 9.2-fold over the low-copy number-expression (pA15a) 
(as seen by comparing strains BO33I1 with BO33I2 in Figure 3-6a). Second, when supplemented 
with 3-methyl-2-oxobutyric acid, the low-copy number-expression of the leuAmutBCD operon 
produced 2.8-fold more odd-chain-iso fatty alcohols than the medium-copy number-expression (as 
seen for strains OB33J1 and OB33J2 in Figure 3-6a).  
Next, I attempted to combine all three modules to produce BLFLs from glucose, which 




PlacUV5-bslpdV-bsbkdAA-bsbkdAB-bsbkdB, PlacUV5-lplA, PecfabH-SafabH, and PlacUV5-maqu2220. To 
reduce the burden imposed by multiple plasmids while maintaining a sufficient enzyme expression 
level, I tried to integrate some operons into the genome. Based on the findings above, I first created 
strain BC43 with a single copy leuAmutBCD from strain BC33. Using the Type II CRISPR-Cas9 
system, I replaced the native promoters of the genomic leuABCD operon with the strong IPTG-
inducible PlacUV5 promoter, and replaced the RBS of leuA (including all regulatory sites) with the 
previously-used strong synthetic RBS. Simultaneously, I replaced the leuA-coding gene with the 
feedback-resistant leuAmutant. However, when the resulting strain BC43 was transformed with 
corresponding plasmids for fermentation, even-chain-iso products predominated over odd-chain-
iso products (as seen for strains BO43I in Figure 3-6a). This result indicated that the leuAmutBCD 
requires very fine-tuning and that a single copy of leuAmutBCD was insufficient to convert all the 
intracellular 3-methyl-2-oxobutyric acid to 4-methyl-2-oxopentanoic acid, further proving that 
pA15a::PBAD-leuA
mutBCD provides optimal expression level for the α-Keto Acid Synthesis 
Module. Consistency in expression parameters indicates that the optimal levels derived in this 
work may be applicable in other systems requiring the use of an α-keto acid pathway.  
Then, I chose lplA as the gene to be integrated into the host cell’s genome; low expression 
was previously determined to be sufficient to fully functionalize the BKD E2 subunit [112]. 
Furthermore, it has been demonstrated that even low-level overexpression of the global regulator 
of fatty acid metabolism fadR increases fatty acid production [7, 48]. Thus, fadR was cloned to the 
same operon of lplA under the control of the PLacUV5 promoter. The synthetic PLacUV5-fadR-lplA 
operon was then integrated into the native ldhA (involved in lactate production) site of strain BC43, 
resulting in strain BC63 (Figure 3-6b). Deletion of ldhA was expected to reduce lactate formation 
during fermentation [25].  
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Strain BC63 was then engineered to produce BLFL with controlled chain structure. To 
produce even-chain-iso BLFLs from glucose, I created strain BO63V by co-transforming the 
plasmids pB5k-maqu2220 and pE2s-alsS-ilvCD into strain BC63 (Table 3-2, Figure 3-6b). When 
fermented in the absence of α-keto acid, BO63V produced 52.4 mg/L of even-chain-iso fatty 
alcohols (Figure 3-6a, Supplementary Figure 3-4). To produce odd-chain-iso fatty alcohols from 
glucose, the plasmid pA8c-leuAmutBCD was further transformed to strain BO63V (Figure 3-6b). 
The resulting strain BO63L produced 122 mg/L of odd-chain-iso BLFLs, comprising 70% of the 
total BLFLs (Figure 3-6a, Supplementary Figure 3-4). Although the odd-chain-iso BLFL pathway 
is less carbon efficient than the even-chain-iso BLFL pathway due to the loss of a CO2 during 4-
methyl-2-oxopentanoic acid biosynthesis, the SaFabH has higher specificity towards 3-
methylbutyryl-CoA (the precursor for odd-chain-iso products) than 2-methyl-propanoyl-CoA (the 




Figure 3- 6 Optimizing α-keto acid biosynthetic pathways in alcohol-producing strains 
containing MaMaqu2220 
(a) Plasmids with different copy numbers and promoters were employed to bear the involved genes 
in different strains. The titers of even-chain-iso, odd-chain-iso, and total alcohol from all the strains 
containing α-keto acid biosynthetic pathways are compared with that of strain BO33D with either 
1 g/L 3-methyl-2-oxobutyric acid or 1 g/L 4-methyl-2-oxopentanoic acid supplementation. (b) The 
complete pathways and genome modifications involved in strain BC63V (purple) and BC63L 











Figure 3- 7 Fed-batch production by strain BO63L 
(a) Time-course plots of SCFL and BCFL titer and cell density. (b) BCFL profile at 85 hours 

















































































Finally, I assessed the performance of strain BO63L in a 1 L glucose fed-batch fermenter 
(Section 3.2.4). After 85 hours of cultivation, BLFLs accumulated to 350 mg/L (Figure 3-7a). The 
concentration of 14-methyl-pentadecanol, the most abundant product, reached 217 mg/L (Figure 
3-7b). Interestingly, straight LCFLs accumulated rapidly after induction, while BLFL titers did not 
increase until 32 h (Figure 3-7a). I suspect that the initial straight-chain alcohol accumulation may 
result from the leaky expression of Maqu2220 prior to induction. Further optimization of 
fermentation conditions (such as pH, air flowing rate, stirring rate, etc.) might improve the 
percentage and yield of BLFL. Overall, these results demonstrate the potential of strain BO63L 
for high-titer production of BLFLs and suggest that further studies might lead to its use on an 
industrial scale. 
3.4 Discussion 
Although alcohol-producing pathways have been previously engineered to produce straight 
LCFLs and short-chain alcohols, little effort has been made to produce BLFLs. In this work, I 
characterized the capability and substrate specificity of four different alcohol-producing pathways 
for BLFL production. I demonstrated the highly selective production of two types of BLFLs (odd-
chain-iso and even-chain-iso) by engineering the upstream pathways for precursor synthesis. I 
obtained high BLFL proportions out of total fatty alcohols (strain BO63L, yielded 80%). I also 
obtained comparable BLFL titers (strain BO63L, 175 mg/L in the absence of any precursor) to 
BCFA titers, despite the extensive additional engineering required for BLFLs production. The 
modular engineering strategy allowed us to apply the knowledge learned from the AAR pathway 
to the new identified Maqu2220 pathway for rapid optimization, quickly yielded strain BO63L 
that produced 350 mg/L BLFLs in a fed-batch fermenter. Because BLFLs can be directly used in 
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skin-care or sunscreen products, and are good candidates for diesel fuels, the production of specific 
BLFL species in high percentages may directly benefit the cosmetics and bioenergy fields.  
Meanwhile, I partitioned the complete pathway into three modules: a precursor formation 
module (the α-Keto Acid Synthesis Module), an acyl-CoA activation and malonyl-ACP 
consumption module (the Acyl-ACP Generation Module), and a final product synthesis module 
(the Alcohol Formation Module). Each module can be separately engineered and tuned for novel 
chemical synthesis. Furthermore, when the tuned modules are combined, the expression level of 
each module can be tuned to avoid imbalance and to improve product titer. I demonstrated 
consistent expression parameters that result in optimal productivities, which can be used for the 
production of other chemicals. Together with previous successes in modular engineering of the 
isoprenoid pathway [129], the FFA pathways [46] and the ester pathways [130], I confirm that 
modular pathway engineering is an effective approach to improve product titer and yield. 
The top-performing strain BO63L produced 350 mg/L BLFLs in fed-batch fermenter, still low 
compared to that of the best straight LCFL-producing strain (3.82 g/L in shake flask) [121]. 
Current pathway is not limited by α-keto acid because increasing the supplemented 4-methyl-2-
oxopentanoic acid from 1 g/L to 8 g/L did not increase BLFL titer (Supplementary Figure 3-3). 
Furthermore, conversion of acyl-ACPs to BLFLs is not likely to be the limiting step due to the 
high conversion efficiency of Maqu2220 [121]. Thus, I believe the current bottleneck lies in the 
Acyl-ACP Generation Module, which requires further engineering to improve BLFL titer and yield. 
Previous engineering strategies developed to optimize free fatty acids production could be 
potentially used to further improve BLFL yield. These strategies include modulation of the fatty 
acid and the phospholipid biosynthesis pathway [131], implementing synthetic control systems to 
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dynamically regulate pathway gene expression [13, 14, 24, 48], and enriching the high-performing 
subpopulation using PopQC [24].  
3.5 Conclusions  
I have constructed and tested the capability of four different alcohol-producing pathways for 
BLFL production in engineered E. coli. Moreover, by engineering the α-keto acid biosynthetic 
pathways and balancing the expression levels of three different modules, I achieved BLFL titers 
of up to 350 mg/L from glucose, and BLFL percentages up to 79%. Overall, this work generates 
pathways and knowledge for the production of BLFLs in high percentages that will have broader 





Supplementary Figure 3-1. Fatty alcohol profiles of strains involved in Figure 3-3b.  
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Supplementary Figure 3-3. Odd-chain-iso fatty alcohol production in strain BO33D with 
different concentrations of 4-methyl-2-oxopentanoic acid supplementation. The data has 
been normalized to the odd-chain-iso fatty alcohol production in strain BO33D with 1g/L 4-
methyl-2-oxopentanoic acid supplementation. 
 
 






























































































Chapter 4: Production of other fatty-acid-
derived chemicals based on the established 
non-natural fatty acid biosynthetic pathway 
4.1 Introduction 
Increasing concerns about national security and the global petroleum supply have driven the 
development of state-of-art technologies for the sustainable production of chemicals, materials, 
and fuels that are currently derived from petroleum [132]. Engineering microbes for chemical 
production is particularly attractive because it allows the conversion of renewable and low-cost 
feedstocks (such as lignocellulosic biomass and CO2) into products with precise structures [55, 
133] without the use of high temperatures and pressures. Currently, extensive research focuses on 
engineering the fatty acid biosynthetic pathway [134-137], and especially on the efficient 
bioconversion of produced fatty acids to other chemicals including alkanes [124], alkenes [50], 
alcohols [138], aldehydes [124], and esters [48]. These chemicals can be used as biofuels [55, 138], 
pharmaceuticals [139], polymer precursors [140], and lubricants [141]. 
The biosynthesis of alkanes and esters are of particularly great interest because they are 
biofuels with promising physiochemical and combustion properties that are similar to those of 
petroleum-based fuels. Like fatty alcohol, fatty acid esters and alkanes can be synthesized from 
the same intermediates of the fatty acid synthetic pathway: fatty acyl-ACP or fatty acyl-CoA. Fatty 
acid esters have been produced by esterifying acyl-CoA with methanol or ethanol using a wax 
ester synthase (AtfA), while alkanes have been generated from fatty aldehyde by aldehyde-




Figure 4- 1 Biosynthetic pathways for alkane and ester production 
The Acyl-ACP Generation Module (Module B) incorporates α-keto acid into the fatty acid 
biosynthetic pathway. The Product Formation Module (Module C) converts branched-chain acyl-
ACPs to alkanes and esters. 
 
Most previously biosynthesized alkanes and fatty acid esters have straight aliphatic chains, 
which have relatively higher freezing points than their petroleum-derived, branched-chain 
counterparts, limiting their low-temperature operability. Thus, there is much impetus to 
biosynthesize fuels derived from branched-chain fatty acids (BCFAs) to such improved properties 
as a lower freezing point and better cold flow. In this chapter, I applied the modular engineering 




4.2 Materials and Methods 
4.2.1 Materials and Media 
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA). 
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased 
from Thermo Fisher Scientific (Waltham, Massachusetts, USA). All primers were synthesized by 
Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl 
Ester Mix), SCFA standards (GLC-20 and GLC-30), and all the other reagents were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4, 
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2, and micronutrients, 
including 3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2, 
and 10 μM ZnSO4) containing 2% glucose and 0.5% yeast extract as carbon sources was used for 
cell growth and fatty alcohol production.  
4.2.2 Plasmids and strains 
Plasmids and oligonucleotides used in this study were listed in Table 4-1. Genes encoding 
Prochlorococcus merinus ADO (ADO), Alicyclobacillus acidocaldarius FabH (AaFabH), and 
Megasphaera elsdenii Pct (Pct) were codon-optimized for E. coli expression and synthesized by 
Integrated DNA Technologies (Coralville, IA, USA), whereas other genes were amplified by PCR 
and assembled into the backbones of BioBrick plasmids [64] using either restriction sites or 





Table 4- 1 Plasmids used in Chapter 4 
Plasmids Replication ori Overexpressed operon Resistance Refs 
pB5k-tesA pBBR1 P lacUV5-tesA(E. coli) Kan
R This study 
pE8c-pct ColE1 PBAD-pct(M. elsdenii) Cm
R This study 
pSa-PecfabH-AafabH SC101 PecfabH-fabH (A. acidocaldarius) Amp
R This study 
pE5c-fadD-atfA pBBR1 PlacUV5-fadD(E.coli)-atfA Cm
R This study 
pE8c-ado ColE1 PBAD-ado(P. merinu) Cm
R This study 
pE8k-lplA ColE1 PBAD-lplA(E. coli) Kan
R This study 
pB5k-tesA-lplA pA15a PlacUV5-tesA-lplA (E. coli) Kan
R This study 
 
Table 4- 2 Strains used in Chapter 4 
Strains Relevant genotype Reference 
CL111 UB1005, attHK022::(plsX’fabH; aadA) fabH::kan [67] 
CL111(△Kan) CL111 △kan Chapter 2 
BC73 BC63 △yjgB This study 
BC14 CL111(△Kan) pSa-PecfabH-AafabH This study 
BA33A BC63 pB5k-aar-lplA, pE8c-ado This study 
BA73A BC73 pA8c-aar-lplA, pB5k-ado This study 
BE33A BC33 pB5k-tesA-lplA, pE5c-fadD-atfA This study 
BC14A BC14 pB5k-tesA, pE8c-pct This study 
BO14D BC14 pB5k-maqu2220, pE8c-pct This study 
 
E. coli DH10B was used for cloning purposes. E. coli strains CL111 [67] was used for 
production purposes. To created strain BC14, plasmid pSa-PecfabH-AafabH was transformed into 
CL111(△Kan) strain, and the SefabH was knocked out by P1 transduction [67]. The genomic yjgB 
was deleted in BC63 strain using a previously described CRISPR-Cas9 gene replacement method 
(Jiang Y. et al. 2015), creating strain BC73. Other strains were created by transforming the 
corresponding plasmids (Table 4-2) into corresponding parental strains, respectively. 
4.2.3 Cell culturing and α-keto acids supplementation 
Overnight cultures were inoculated 2% v/v into M9 minimal medium (in section 4.2.1) with 
corresponding antibiotics for adaptation. Overnight cultures in minimal medium were then used to 
inoculate 5 mL of the same fresh minimal medium with an initial OD600 of 0.08. Cells were induced 
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with proper inducers (1mM IPTG, 0.4% arabinose, and/or 200 nM aTc) when OD600 reached 0.8 
or as otherwise specified. For α-keto acids supplementation experiments, one of the α-keto acids 
(3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, or glycolic acid) was added at OD600 
= 0.8 to a final concentration of 1 g/L. For alkane production experiments, 0.5 mL decane was 
added to each sample as an organic layer to extract alkanes. For ester production experiments, 
ethanol or isopropanol was added at a final concentration of 5% v/v, respectively. Cells were 
harvested three days after induction.   
4.2.4 Quantification of the products 
For the quantification of diols and fatty acid esters, 1 mL of cell culture was acidified with 
100 μL of concentrated HCl (12N). Diols and esters were extracted twice with 0.5 mL of ethyl 
acetate. For derivatization of diols, 200 μL of supernatant from each sample was transferred to 2 
mL clear glass GC vials (Agilent Technologies, Santa Clara, CA), mixed with 200 μL of 
N,OBis( trimethylsilyl)trifluoroacetamide with 1% v/v chlorotrimethylsilane, and incubated at 
60 °C for 2 h. Both diol derivatives and fatty acid esters were quantified using a GC-MS (Hewlett-
Packard model 7890A, Agilent Technologies) equipped with a 30 m DB5-MS column (J&W 
Scientific) and a mass spectrometer (5975C, Agilent Technologies) or a FID (Agilent Technologies) 
detector. For each ester sample, the column was equilibrated at 80 °C, followed by a ramp to 
280 °C at 30°C/min, and was then held at 280 °C for 3 min. For each diol sample, the column was 
equilibrated at 80 °C, followed by a ramp to 300 °C at 20°C/min, and was then held at 300 °C for 
3 min. Individual peaks were identified by comparing their retention time to those of diol standards 
(mixture of 12-hydroxy-1-dodecanol, 14-hydroxy-1-tetradecanol and 16-hydroxy-1-hexadecanol, 
prepared and derivatized identically to samples) or FAEE mixtures (Sigma Aldrich). 
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Concentrations of each component were determined by comparing the area of each peak to a 
standard curve generated by corresponding standards eluted using the same method.   
To quantify alkanes, the decane organic layer was extracted and diluted 10 times. Then the 
samples were quantified using a GC-FID (Agilent 6890A) equipped with a 30 m Rtx-1 column 
(Restek, Bellefonte, PA). For each sample, the column was equilibrated at 45 °C for 4 min, 
followed by a ramp to 300 °C at 15°C/min, and was then held at 300 °C for 5 min. Individual 
alkane peaks were identified by comparing their retention time to those of standard alkane 
solutions (Sigma Aldrich). Concentrations of each alkane were determined by comparing the area 
of each alkane peak to a standard curve generated by standard alkane mixtures eluted using the 
same method.  
Product titer for each strain was measured in biological triplicate (starting from three different 
colonies), and average values are reported. 
4.3 Results 
4.3.1 Testing alkane-producing pathways in BCFA-producing strains 
Based on the optimal expression level for all three Modules in Chapter 3, I expanded the 
application of Module (C) for various chemical productions (Figure 3-1). First, I focused on 
alkane, another important product derived from the fatty acid synthetic pathway. The alkane-
producing pathway is well-known in cyanobacteria and plants [124, 142]. The key enzyme, 
aldehyde-deformylating oxygenase (ADO), has been isolated and characterized to catalyze the 
reducing reaction from aldehyde to alkanes. In this chapter, I selected AAR to construct the alkane-
producing pathways, because I suspected that Maqu2220 already contained a subunit functioning 
as ADH, which would direct the metabolic flux towards alcohol production. In order to produce 
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branched-chain alkane, the ado gene from Prochlorococcus merinus [143-146] that encodes ADO 
was overexpressed in strain BO33A, to generate strain BA33A (Figure 4-1). When cultivated in 
37°C without supplementation, strain BA33A produced 8 mg/L total alkane, and 1.7 mg/L 
branched-chain alkane. When 4-methyl-2-oxopentanoic acid was supplemented, the BC alkane 
titer increased to 10 mg/L, comprising 74% of total alkane production (Figure 4-2) and 
representing the highest BC alkane titer and percentage published to date. 
 
Figure 4- 2 Branched-chain alkane production from strain BA33A 
 
Many studies have shown that the deletion of E. coli endogenous alcohol dehydrogenase 
increases the aldehyde accumulation and thus improves the alkane production [147, 148]. As 
shown in Figure 3-2c, endogenous ADH YjgB has a high specificity toward long-branched-chain 
aldehyde, so I deleted the yjgB gene in strain BC63 genome by CRISPR-Cas9, followed by 
transforming corresponding plasmids into the resulting strain BC73, hoping the branched-chain 
alkane production would improve in the resulting strain, BA73A. However, BA73A produced 
similar amounts of alkane regardless of whether α-keto acid was supplemented or not (data not 
shown). One possible reason might be that the alkane generation rate of ADO was so slow that the 
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deletion of endogenous adhs could not help to redirect the flux towards alkane. Or there are too 
many endogenous adhs that could reduce the long-branched-chain aldehyde to alcohols, thus the 
deletion of a single adh gene (yjgB) would not decrease the alcohol generation rate. Other strategies, 
such as overexpression of fatty alcohol oxidase (FAO) and/or manipulation all the factors related 
to fatty aldehyde dynamic pools [149], might further improve the branched-chain alkane 
production. 
4.3.2 Assembling the ester-producing pathway in BCFA-producing strains 
The production of fatty acid ethyl esters (FAEE), the major component of biodiesel, has been 
demonstrated in E. coli. However, the microbially-produced FAEE primarily consist of ethyl-
palmitate, which has a melting point of 23oC, and so is not suitable in cold weather. Alternatively, 
ethyl-anteiso-methyl-palmitate does not freeze until the temperature reaches 3.8oC, a much more 
amenable temperature for direct usage in a variety of climates, demonstrating the value of 
BCFAEEs [150, 151].  
 
Figure 4- 3 Fatty acid ester production from strain BE33A 




Just as for the BCFL production, I first focused on the Module C to produce BCFAEEs from 
BCFAs. Strain BE33A was constructed by transforming the plasmid pB5k-fadD-atfA into BCFA-
producing strain BC33A (Table 4-2). Free BCFAs were converted into branched-chain acyl-CoAs 
by an acyl-CoA synthase (encoded by fadD) and then transesterified to BCFAEEs by a wax ester 
synthase (encoded by atfA). When cultivated with supplementation of 1 mg/L of 4-methyl-2-
oxopentanoic acid and 5% ethanol, strain BE33A produced 71 mg/L FAEE, with BCFAEE 
comprising 66.9% of the total FAEE (Figure 4-3).  
Finally, I attempted to generate branched-chain esters with branches at both termini 
(branched-chain fatty acid isopropyl esters), through the in vivo transesterification of isopropanol 
rather than ethanol. Strain BE33A was supplemented with 5% isopropanol at the point of 
induction. Fatty acid esters from BE33A, observed by GC-MS, contained branches at both the 
fatty acyl terminus and the ester terminus, reaching 68 mg/L and 61.4% of the total fatty acid 
isopropyl esters produced (Figure 4-3). There is no data describing the freezing point of these 
branched-chain fatty acid isopropyl esters (BCFAIEs), but theoretically, the freezing point of the 
double-branched fatty acyl esters will be lower than that of the esters with a single branched 
terminus, increasing the value of the resultant fuel. 
4.3.3 α, ω-diol production by switching the fabH and engineering the 
precursor formation module 
After exploring the different possibilities for product generation module (Module C) to 
produce branched-chain alcohols, alkanes and esters, I sought to engineer the acyl-CoA activation 
(Module A) and malonyl-ACP consumption module (Module B) to incorporate other ω-functional 
groups into fatty acid chain (Figure 3-1). I first chose ω-hydroxy group, because ω-hydroxy fatty 
acids and α,ω-diols are valuable precursors to polyesters [152], and the enzyme Pct from M. 
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elsdenii has been identified to produce 2-hydroxyacetyl-CoA from 2-hydroxyacetic acid (glycolic 
acid).  
 
Figure 4- 4 Biosynthetic pathways to generate ω-hydroxy products 
The Acyl-ACP Generation Module (Module B) incorporates ω-hydroxy-acyl-CoA into the fatty 
acid biosynthetic pathway. The Product Formation Module (Module C) converts ω-hydroxy-acyl-
ACP to ω-hydroxy acid and diols. 
 
I first sought to engineer the Module B by replacing E. coli native fabH with a ω-hydroxy 
acyl-CoA-specific fabH using similar strategy described in Chapter 2. Because no FabH has ever 
been reported to uptake ω-hydroxy acyl-CoA, I selected the FabH from Alicyclobacillus 
acidocaldarius, which was reported to uptake 3-hydroxybutyryl-CoA as a substrate. Strain BC14 
carrying AafabH was constructed from parental strain CL111(△Kan) through P1 transduction in 
the same way as strain BC13. Then plasmids pE8c-pct and pB5k-maqu2220/pB5k-tesA were 
transformed into strain BC14 to create the producing strains BC14A and BO14D, respectively. 
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However, when glycolic acid was supplemented in the cell culture, no ω-hydroxy products were 
detected in either strains. This result indicated that either AaFabH or FASII elongation enzymes 
could not uptake ω-hydroxy substrates. 
4.4 Discussion 
In this chapter, I applied the modular BCFA synthetic pathway to generate biofuels with 
desirable cold-flow properties for specific fuels. Strain BA33A can produce branched-chain alkane 
with a percentage of 74%, which can be readily used as jet fuel. Similarly, strain BE33A, which 
can produce BCFAEE and BCFAIE in high percentages, will also benefit the biodiesel industry. 
The next step was to expand the profile of the products from this NNFA biosynthetic pathway 
to include bifunctional chemicals. Here I started by incorporating the ω-hydroxy group, but was 
unsuccessful, probably due to the unsuitable FabH. On the other hand, to generate ω-hydroxy fatty 
acid, the ω-hydroxy group can also be introduced by P450 enzymes after FASII elongation steps 
[152]. I tried this pathway to produce α, ω-diols, but it suffered from low titers and the significant 
co-production of fatty alcohols (data not shown). This fact also demonstrated the superiority of 
this NNFA synthetic pathway to produce ω-functionalized fatty acid derivatives in a high 
percentage and called for an effective method to screen and select for suitable FabHs. 
4.5 Conclusion 
In this chapter, I engineered the BCFA-producing strains to generate branched-chain alkanes 
and esters in high percentages, which can be readily used as biofuels with desirable cold-flow 
properties. I also explored the possibility of producing ω-hydroxy fatty acids and α,ω-diols by 




Chapter 5: Establish a cell-free platform for 
producing fatty acid and derivatives 
5.1 Introduction 
The success of BCFA production in engineered E. coli demonstrated the versatility of E. coli FASII 
elongation enzymes in accepting substrates with branched terminal groups, paving the way for the 
bioproduction of bifunctional fatty-acid-based chemicals, such as ω-hydroxy acids, ω-ethenyl 
acids, ω-ethynyl acids, and ω-azido acids. These chemicals have appealing applications: ω-
hydroxy acids are monomer building blocks for polymers, and acids with ethenyl, ethynyl, or azido 
groups have the potential for protein tagging and labelling in protein chemistry. In addition, the 
engineered BCFA synthetic pathway can provide a suitable platform to test the capacity of the 
FASII enzymes to uptake the ω-functionalized substrates, while the modular pathway engineering 
strategy can simplify the test by decoupling it from the generation of acyl-CoA precursors.  
However, even with the supplementation of those specific α-keto acids or acyl-CoA precursors, 
there would still be several obstacles to running the test in vivo, including the intracellular transport 
barriers of the precursors and the toxicity of those bi-functional molecules to the cells. Meanwhile, 
the in vitro system offers a complementary approach, which can also overcome other shortages for 
in vivo biomanufacturing practices, most notably, these are the cell’s inherent limitations (mainly 
the cost of carbon and energy for cell growth, maintenance, and byproduct formation [64]) and the 
unwieldy complexity of cells [64-66].  
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Although the in vitro reconstitution of the fatty acid synthase in E. coli has been achieved 
using purified enzyme systems [88], I chose crude lysates to build this biosynthetic pathway for 
several reasons: 1) The fatty acid productivity could be easily affected by the molar ratio of the 
FASII enzymes, and the fatty acid overproducing cell lines have molar protein ratios that are close 
to optimal; 2) The native metabolic enzymes and cofactor regeneration in the crude lysates will 
result in a higher titer than that of the purified systems, which will make identification of products 
much easier; 3) The crude lysates inherently provide the context of native-like metabolic networks 
[153-156].  
Quick and efficient biosynthesis of several chemicals has been achieved with high 
productivities by cell-free metabolic engineering (CFME) using crude lysates, such as mevalonate 
[155], n-butanol [153], and 2,3-butanediol [157]. In all these cases, the enzymes involved in the 
metabolic pathways have been overexpressed. However, considering the robustness and integrity 
of FASII enzymes, I used cell endogenous FASII enzymes without any engineering or 
overexpression in this work (except heterologous overexpressed FabH). I used several strategies 
to construct and optimize the CFME reaction and achieved both straight-chain and branched-chain 
fatty alcohol production in vitro. 
5.2 Materials and Methods 
5.2.1 Strains, plasmids and media 
Strains used in this study were listed in Table 5-1. Genes encoding E. coli accABCD was 
amplified from the genome and assembled into the pE8c backbone using Golden-Gate DNA 
assembly method [65].  
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2×YTPG media (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, 7 g/L KH2PO4, 3 g/L 
K2HPO4, 18 g/L glucose) without any antibiotics was used to cultivate cells for lysate preparation.  
Table 5- 1 Strains used in Chapter 5 
Strains Relevant genotype Reference 
JBEI-9018 MG1655 ΔfadE, araD: acpS (C. glutamicum), pB5k-maqu2220 [121] 
DH1acc DH1(ΔfadE) pE8c-accABCD This study 
BC13A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-SafabH, pB5c-tesA-
bkd 
Chapter 2 




5.2.2 Cell extract preparation 
Cell lysates were prepared using a previously published protocol [158]. In detail, E. coli cells 
were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were inoculated 2% 
v/v into 2×YTPG minimal medium (described in section 5.2.1) at 37 °C with vigorous shaking at 
250 rpm. When OD600 reached 0.8, cells were induced with proper inducers (1mM IPTG, 0.4% 
arabinose and/or 200 nM aTc, or as otherwise specified) and grown for 4h at 30 °C. The cells were 
harvested by centrifuging at 8000 g at 4 °C for 15 min and were washed twice with ice-cold S30 
buffer (10 mM Tris-acetate (pH8.2), 14mM Mg(Ac)2, and 60 mM potassium glutamate). Then the 
pelleted wet cells were weighed and suspended in 0.8 mL of S30 buffer per1g wet cell mass. 
Suspended cells were lysed using a Qsonica Sonicator Q700 (Qsonica, Newtown, CT) with a 1.6 
mm diameter probe at frequency of 20 kHz and 50% of amplitude. The various input energies 
(Joules) were used, and the optimal input energies for different strains were identified by following 
cell-free protein synthesis (CFPS) reactions. The lysates were then centrifuged twice at 21,100 g 
at 4 °C for 15 min. All the prepared cell extracts were flash frozen in liquid nitrogen and stored at 
-80 °C until use. 
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5.2.3 Protein quantification in cell lysates and CFPS reactions 
The total protein concentration of the extracts was measured by Bradford protein assay with 
a bovine serum albumin standard. The extracts were subsequently run on a 12% SDS-PAGE gel 
with Coomassie-blue staining analysis. 
The CFPS reactions were carried out following a published protocol [158]. In detail, a 25 μl 
CFPS reaction was prepared by mixing the following components in a 1.5 mL microtube: 1.2 mM 
ATP; 0.85 mM each of GTP, UTP, and CTP; 34.0 mg/mL L-5-formyl-5, 6, 7, 8-tetrahydrofolic 
acid (folinic acid); 170.0 mg/mL of E. coli tRNA mixture; 130 mM potassium glutamate; 10 mM 
ammonium glutamate; 12 mM magnesium glutamate; 2 mM each of 20 amino acids; 0.33 mM 
nicotinamide adenine dinucleotide (NAD); 0.27 mM coenzyme-A (CoA); 1.5 mM spermidine; 1 
mM putrescine; 33 mM phosphoenolpyruvate (PEP); 13.3 mg/mL plasmid pJL1-sfGFP; 100 
mg/mL T7 RNA polymerase, and 10 mg/mL of cell extract. The CFPS reactions were carried out 
at 37 °C for 24 h. For each sample, 2 μL of reaction mix was diluted with 48 μL of purified water, 
and the fluorescence of active sfGFP was measured by an Infinite F200PRO (TECAN) plate reader 
at excitation and emission wavelengths of 485 and 528 nm, respectively.  
5.2.4 CFME reactions and products quantification 
Reactions were carried out at 37 °C in 25 μl volumes for 4 h (or as otherwise specified). Each 
reaction consisted of mixing the cell-extracts along with 8 mM magnesium glutamate, 10 mM 
ammonium glutamate, 134 mM potassium glutamate, 10 mM K2HPO4 (pH = 7.2), 100mM BisTris, 
and various substrates and cofactors. Reactions were terminated by adding ethyl acetate in a 1:1 




5.3.1 Cell-free metabolic engineering for fatty acid production 
To achieve cell-free biosynthesis of fatty acids, I first used strain BC13A for lysis and extract 
preparation. Various conditions were set up to produce straight-chain or branched-chain fatty acid 
as shown in Table 5-2 (A-D). The reaction mixtures were incubated at 37 °C for 4 h, then the 
amount of fatty acids in each sample was measured using previous analytical methods. As this was 
the first trial to test whether in vitro production of fatty acid from CFME reaction was even feasible, 
so I just used a well-established reaction protocol from Jewett Lab in Northwestern University. 
Further investigation and/or optimization of the reaction buffer setting/running time might be 
performed after the verification of the feasibility.  
However, more than 30 mg/L C18:0 fatty acid (stearic acid) was observed in all the conditions 
(Figure 5-1), which the exceeded the theoretical yield (9 mg/L in the form of C18:0 fatty acid) 
calculated from the supplied NADPH. I sought to trace the source of the excess FFA by setting up 
different control reactions (Table 5-2 E-H). A high amount of FFA was detected in all the sources 
(Figure 5-1), including water, all the reagents, and the cell extract, which indicated that the detected 




Table 5- 2 Reactions for fatty acid production from CFME 
 A B C D E F G H 
15× SS 1× 1× 1× 1× 1× 1× -- -- 
glucose (mM) 200 -- -- -- 200 -- -- -- 
acetyl-CoA -- 25 -- 25 -- 25 -- -- 
α-keto acid (g/L) -- -- 1 1 1 1 -- -- 
K2HPO4 (mM) 10 -- 10 -- 10 -- -- -- 
Bis Tris Buffer (mM) 100 -- 100 -- 100 -- -- -- 
NAD+ (mM) 0.5 -- 0.5 -- 0.5 -- -- -- 
NADP+ (mM) 0.5 -- 0.5 -- 0.5 -- -- -- 
NADPH (mM) -- 1 -- 1 -- 1 -- -- 
ATP (mM) 1 1 1 1 1 1 -- -- 
CoA (mM) 0.5 -- 0.5 -- 0.5 -- -- -- 
BC13A lysate (mg/mL) 10 10 10 10 -- -- -- 10 
 
 
Figure 5- 1 Fatty acid production from CFME reactions 
 
Because the amounts of detected FFA were comparable, indicating they were introduced from  
common steps, I assumed that the FFA contamination resulted from three external major sources: 
the surface of the tubes, the water used, and the incubation process. The effect of each factor was 
quantified by setting up various reactions (Supplementary Table 5-1). The results showed that the 
contamination induced during incubation was negligible (data not shown), but a large amount of 
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C16:0 and C18:0 fatty acids was introduced from the tube and water (Supplementary section). For 
a 25 μL reaction in a 1.5 mL tube, the C18:0 fatty acid contamination from the environment was 
roughly 20 mg/L. 
5.3.2 Cell-free metabolic engineering for fatty alcohol production 
Considering the difficulty of eliminating FFA contamination from the environment, I switched 
to the fatty alcohol pathway for this research. After confirming that no fatty alcohol would be 
introduced from the environment, I lysed two strains to generate cell extracts for straight-chain 
and branched-chain alcohol productions. Strain JBEI-9018 was reported to produce the highest 
amount of straight-chain alcohols to date [121], while BO33D strain is currently the best 
performing strain for branched-chain alcohol production. 
I first tested the feasibility of the cell extracts to produce fatty alcohols in vitro by setting up 
a series of reactions (Table 5-3). Similarly, I used the same well-established protocol to run the 
reactions. Reaction O was set to detect the trace amount of alcohol in all the reagents and cofactors, 
while reactions A- and B- were used to evaluate the alcohol amounts in the cell extracts. All the 
reactions started with acetyl-CoA and malonyl-CoA as the substrate to uncouple the FASII 
synthesis from other endogenous reactions (such as glycolysis), and 4-methyl-2-oxopentanoic acid 




Table 5- 3 Reactions to produce fatty alcohols from CFME 
 O A- A+ B- B+ 
JBEI-9018 
lysate 
-- 10 mg/mL 10 mg/mL -- -- 
BO33D lysate -- -- -- 10 mg/mL 10 mg/mL 
Acetyl-CoA 25 mM -- 25 mM -- -- 
Malonyl-CoA 0.5 mM -- 0.5 mM -- 0.5 mM 
Keto acid 1 g/L -- -- -- 1 g/L 
NADPH 1 mM -- 1 mM -- 1 mM 
ATP 1 mM -- 1 mM -- 1 mM 
15× SS 1×  1×  1× 
 
The comparison between A- and A+ indicated that 2 mg/L of C18:0 alcohol (stearyl alcohol) 
was produced in vitro. Similarly, with supplemented α-keto acid, 1 mg/L of C17:0 iso alcohol (15-
methyl-1-hexadecanol) was generated from reaction B+ (Figure 5-2). Both results demonstrated 
that all the enzymes involved in alcohol producing pathway, including FASII elongation enzymes, 
BKD, and Maqu2220 were active in the cell lysates. However, more than 20 mg/L of C16:0 alcohol 
was detected in both cell lysates, even without any substrates or cofactors, which made the 
identification of the in vitro produced portion impossible.  
 




5.3.3 Improve the cell-free platform for fatty alcohol production  
I reasoned that a large amount of C16:0 alcohol might be generated during the post-induction 
incubation, that is, once the Maqu2220 was overexpressed, it would immediately convert acyl-
ACPs to alcohols during the incubation before lysis. Therefore, I designed two ways to 
differentiate this portion with in vitro produced portion: one way is to attenuate the in vivo 
produced portion, and the other is to increase the in vitro produced portion. 
I first decreased the cell extract concentration in hope to directly decrease the in vivo produced 
portion. However, when the cell extract concentration was decreased to 1 mg/mL, although no 
C16:0 alcohol was detected in all the reactions, the concentrations of C18:0 and C17:0 iso products, 
which were identified as synthesized in vitro, were also below the detection limit. This result 
indicated that the FASII enzymes and/or the Maqu2220 enzyme need to be accumulated to a 
threshold to run the cell-free reactions and to produce detectable amount of the alcohols. While 
under this threshold, it is almost impossible to omit the in vivo produced portion using the cell 
extract from a single strain. 
As direct decreasing the in vivo produced portion was unsuccessful, I sought to increase the 
in vitro produced portion by studying the necessity of the substrates and cofactors, i.e. acetyl-CoA, 
malonyl-CoA, and NADPH.  Some of the cofactors might either already exist or be regenerated in 
the cell lysate, but the low titer in section 5.3.2 demonstrated that at least one of the substrates or 
cofactors would be the limiting step. Reactions A1-A5 were carried out using the cell extract from 
JBEI-9018 (Table 5-4), and the results clearly showed that external malonyl-CoA is required for 
in vitro fatty alcohol production (Figure 5-3A). I also evaluated the impact of the malonyl-CoA 
amount on in vitro branched-chain fatty alcohol production by setting up reactions B1 to B3 with 
various malonyl-CoA concentrations (Table 5-4). When the malonyl-CoA concentration was 
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increased by 6-fold, the C17:0 iso titer increased by 8-fold (Figure 5-3B). Again, no branched-
chain product was observed in reaction B3 lacking malonyl-CoA. 
Table 5- 4 Cofactor necessity test for fatty alcohol production from CFME 
 A1 A2 A3 A4 A5 B1 B2 B3 











BO33D BO33D BO33D 
Acetyl-CoA (mM) 25 -- 25 -- 25 -- -- -- 
Malonyl-CoA (mM) 0.5 -- -- 0.5 0.5 3 0.5 -- 
Keto acid (g/L) -- -- -- -- -- 1 1 1 
NADPH (mM) -- 1 1 1 1 1 1 1 
ATP (mM) 1 1 1 1 1 1 1 1 
15× SS 1× 1× 1× 1× 1× 1× 1× 1× 
 
 
Figure 5- 3 The role of different cofactors in fatty alcohol production from CFME reactions 
 
5.3.4 Straight-chain fatty alcohol production from lysate mix 
Although I found that the malonyl-CoA is the limiting resource for in vitro production, I could 
not supplement it to a very high concentration, due to its solubility and high price. Thus, I next 
sought to overexpress the accABCD operon to endogenously produce malonyl-CoA from acetyl-
CoA. However, the overexpression of accABCD was reported to increases the rate of fatty acid 
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biosynthesis. Considering that a large proportion of C16:0 alcohol was already generated in vivo 
before the cell lysis process in a maqu2220 overexpressed strain, I decided to separate the 
overexpression of accABCD from the maqu2220 overexpressed strain. Here I overexpressed these 
two operons in two strains and mix their cell lysates to reduce the in vivo production. 
The accABCD operon was overexpressed in strain DH1(△fadE) to create strain DH1acc. The 
lysate of DH1acc was mixed with that of JBEI-9018 at two different ratios for a rough optimization 
(Table 5-5 A0 to A2 vs. B0 to B2). The total amount of the cell lysates was kept at 10 mg/mL to 
guarantee the performance of FASII enzymes in vitro. I used glucose rather than acetyl-CoA as 
the substrate, because glycolysis has been reported to be active in cell-extract. Considering about 
the conversion of glucose to acetyl-CoA, and their solubilities and prices, the use of glucose would 
undoubtedly increase the acetyl-CoA pool in the reaction, which might increase the product titer. 
Additionally, malonyl-CoA was supplemented in reaction A2 and B2 to evaluate the accABCD 
efficiency.  
Table 5- 5 Mix and match approach for straight-chain alcohol production from CFME 
 A0 A1 A2 B0 B1 B2 
JBEI-9018 (mg/mL) 9 9 9 5 5 5 
DH1acc (mg/mL) 1 1 1 5 5 5 
Glucose (mM) -- 200 200 -- 200 200 
Malonyl-CoA (mM) -- -- 0.5 -- -- 0.5 
K2HPO4 (mM) 10 10 10 10 10 10 
Bis Tris Buffer (mM) 100 100 100 100 100 100 
NAD+ (mM) 0.5 0.5 0.5 0.5 0.5 0.5 
NADP+ (mM) 0.5 0.5 0.5 0.5 0.5 0.5 
CoA (mM) 0.5 0.5 0.5 0.5 0.5 0.5 
15× SS 1× 1× 1× 1× 1× 1× 
 
Surprisingly, no fatty alcohol was detected in the cell mix (reaction A0 and B0), which 
demonstrated the effectiveness of the mixture in reducing the final concentration of in vivo 
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produced alcohols. Also, no fatty alcohol was generated in vitro in reactions A1 and A2, indicating 
that the Maqu2220 amount was not sufficient when the JBEI-9018 cell extract concentration was 
only 1 mg/mL. Reaction B1 produced 5 mg/L total fatty alcohol, a 2.5-fold enhancement compared 
to the titer of reaction A+ in section 5.3.2 (Figure 5-5), as expected that glucose will yield a higher 
titer than acetyl-CoA when used as the sole substrate. Moreover, reaction B2 produced 7 mg/L 
total fatty alcohol, indicating that AccABCD amount in this reaction needed further optimization.  
 
Figure 5- 4 Fatty alcohol production from lysate mix 
 
5.4 Discussion 
In this chapter, I tried to develop a new cell-free framework for in vitro fatty acid production. 
Unlike previous published CFME, this framework relied heavily on E. coli native fatty acid 
biosynthetic pathway. Once the enzyme catalyzing the final step, Maqu2220, was overexpressed 
in the strain, fatty alcohols were accumulated even before the cells were lysed. Therefore, how to 
differentiate the in vitro synthesized products from in vivo products generated after induction 
remained a big challenge. Here I decreased the in vivo proportion of the fatty alcohol in the reaction 
by diluting the JBEI-9018 cell extract with the cell extract from a non-alcohol-producing strain. 
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The result is a proof-of-concept for both straight-chain and branched-chain fatty alcohol 
production via CFME.  
Although I have achieved the in vitro alcohol production, a lot of parameters and conditions 
could be further investigated and optimized. First, there are two different reaction buffers used in 
Jewett Lab, gluconate-based buffer and acetate-based buffer. Here I chose gluconate-based buffer 
due to its excellent performance in 1-butanol production, but I did not have a solid evidence that 
the same buffer will improve long-chain alcohol production. Second, although I have identified 
that malonyl-CoA is the rate-limiting factor, the limits for the maximum amounts of all the 
substrates and cofactors are still unknown. Then, by careful examination, it is highly possible that 
the titer would increase by several folds using the maximum limits of all the reagents. 
More importantly, after characterizing the maximum limit of all the reagents (which indicate 
the reaction capacity), the amounts of enzymes could also be tuned to improve the reaction capacity. 
For example, the overexpression of FASII enzymes individually in the cells for lysate preparations, 
followed by mixing and matching lysates in cell-free cocktails might provide another strategy to 
increase the reaction capacity and dilute the in vivo portion of the fatty alcohol while enhancing 
the in vitro production. However, because FabH plays an essential role in incorporating ω-
functionalized acyl-CoA, E. coli native FabH needs to be cleared in all the cell extracts. The △fabH 
strain in the K.O. collection is a promising parental strain, but the effects of its endogenous 
regulations on protein synthesis remain unclear. For instance, when pA5a-maqu2220 plasmid was 
transformed into the △fabH strain, the cells grew very slowly (data not shown), and no Maqu2220 
was detected by SDS-PAGE (Supplementary Figure 5-1).  
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Therefore, to further improve the titer for either scale-up production or product identification, 
a large number of reactions are required to be carried out to optimize the reaction buffer, the 
reaction condition, the optimal amount of all the reagents and the ratio of the cell extracts. 
Meanwhile, cell-free protein synthesis (CFPS) offers a complementary solution to fast enrich 
the enzymes separately before adding into the reactions. The CFPS-ME framework will also 
enable rapid prototyping of ω-functionalized fatty alcohol production from the combination of 
FASII with specific FabH. With the progress of bioinformatics, this platform can be further applied 
for fast screening of optimal enzyme combinations for the production of bifunctional fatty acid 
derivatives. 
5.5 Conclusion 
In this chapter, I established a new cell-free framework for in vitro fatty alcohol production 
and characterized the necessity of several cofactors. The production of both straight-chain and 
branched-chain fatty alcohol from this cell-free framework has been achieved. In addition, I 
overcame a major obstacle arising from the fact that fatty acid synthesis is an endogenous pathway. 
A large proportion of fatty alcohol was produced in vivo during the post-induction incubation time 
but was diluted in the final reaction solution through the mix-and-match approach. This result is a 
proof-of-concept for fatty alcohol production via CFME and provides guidance for future CFPS-
ME frameworks to produce bifunctional fatty acid derivatives, while intensive optimizations are 
still needed before the goal could be achieved. 
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Supplementary Materials  
Quantification of FFA contamination from three major sources. 
Steps:  
1. Prepare the reactions as listed below 
Supplementary Table 5-1 Recipes for quantification of FFA contamination  
 1 2 3 4 5 6 7 8 9 
Water (μL) 25 50 300 50 100 150 300 500 1000 
Tube (mL) 0.5 0.5 0.5 1.5 1.5 1.5 1.5 1.5 1.5 
Incubation Yes No No Yes No Yes No Yes No 
Ethyl Acetate (μL) 25 25 150 50 50 150 150 500 500 
 
1) For samples that need incubation (1, 4, 6, 8), add the indicated amount of water into 1.5 mL 
tubes and incubate at 37 °C for 4 h; 
2) Add the same amount of water into those tubes. For sample 1, transfer into 0.5 mL tubes for 
extraction; 
3) Prepare the samples 2, 3, 5, 7, 9; 
2. Extract each sample with the indicated amount of ethyl acetate twice and derivatize and inject 
as usual; 
3. Normalize the final concentration as the concentration in water; 
4. Calculate the FA concentrations in all the samples 












Chapter 6: Conclusion and future directions 
6.1 Conclusions 
In this work, I have established a modular pathway for producing NNFA and derivatives 
production. To start, I achieved branched-chain fatty acid production. In Chapter 2, I directed the 
carbon flux to the synthesis of BCFAs by replacing the acetyl-CoA-specific E. coli FabH, the only 
β-ketoacyl-(acyl-carrier-protein) synthase that catalyzes the initial fatty acid condensation reaction, 
with a branched-chain-acyl-CoA-specific FabH, enhancing BCFA titer by 81-fold over a strain 
containing both acetyl-CoA- and branched-chain-acyl-CoA-specific FabHs. I further discovered 
that the overexpression of BKD, a member of the 2-oxoacid dehydrogenase family needed to 
synthesize branched-chain-acyl-CoA precursors, is toxic to E. coli due to depletion of the protein 
lipoylation capacity. Engineering a complementary protein lipoylation pathway alleviated the 
toxicity and improved BCFA production to 276 mg/L and 85% of total free fatty acids, the highest 
BCFA titer and percentage to-date. Furthermore, I achieved fine-tuning of BCFA branch positions 
by engineering the upstream pathway to control the supply of branched-chain acyl-CoAs, 
eventually producing 181 mg/L BCFA at 72% of total FFA from glucose.  
In Chapter 3, I partitioned the complete pathway into three modules: a precursor formation 
module (the α-Keto Acid Synthesis Module), an acyl-CoA activation and malonyl-ACP 
consumption module (the Acyl-ACP Generation Module), and a final product synthesis module 
(the Alcohol Formation Module). I engineered and tuned each module separately and combined 
the optimal modules to produce a high percentage of branched fatty alcohols from glucose. In 
Chapter 4, I further utilized this modular pathway engineering strategy to produce branched-chain 
alkanes and esters. I also tested the feasibility of ω-hydroxy fatty acid production by engineering 
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the precursor formation module. In Chapter 5, I moved the modular NNFA synthetic pathway into 
a new cell-free framework to give a proof-of-concept for in vitro production of fatty acid 
derivatives and provided guidance for future CFPS-ME framework to produce bifunctional fatty 
acid derivatives. 
Overall, this work establishes a platform for the microbial synthesis of branched biofuels and 
chemical in high percentages, paving the way for bioproduction of structurally-defined molecules 
with desired properties. 
6.2 Future directions 
In this work, although I have established a modular pathway platform to produce non-natural 
fatty acids, I have achieved the production of only branched-chain fatty acid and derivatives. 
Diversifying the ω-terminal structure requires comprehensive studies on the precursor formation 
module and the acyl-CoA activation and malonyl-ACP consumption module. The enzyme 
selection, screening, and pathway prototyping can be facilitated by bioinformatics and the CFPS-
ME framework. Thus, one future direction would be the optimization of all the factors in current 
CFME framework, and the establishment of an improved CFPS-ME platform to perform the 
prototyping work. 
Meanwhile, although the titer of straight-chain fatty acid and alcohol production can reach 
more than 3 g/L, the results from this dissertation showed that their branched-chain counterparts 
can be produced only at the level of 200 mg/L. Since the low titer might result from the metabolic 
burden caused by protein synthesis and/or product accumulation, studying the metabolic limits of 
the engineered strains will be another future direction. In detail, the burden caused by protein 
synthesis, NADP+/NADPH recycling, and BCFA intracellular distribution, are potential research 
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targets to study about in the fatty acid synthetic pathway. In addition, the heterogeneity of 
producing cells has been demonstrated to affect ensemble production [22, 23], so studies on cell-
to-cell variations based on this platform are other potential directions, including the strategy to 
enrich the high-producing variants and ultimately enhance product titers. These studies will 
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